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ABBREVIATIONS 
 
AMs   Alveolar Macrophages 
APC   Adenomatous polyposis coli protein 
APC   Antigen Presenting Cell 
BLM   Bleomycin 
CBP   CREB Binding Protein 
CI    Confidence Interval  
CK2   Casein Kinase 2 
CCR   Chemokine Receptor 
COPD   Chronic Obstructive Pulmonary Disease 
CTGF   Connective Tissue Growth Factor 
CXCL   CXC chemokine 
CXCR  Chemokine CXC Receptor 
CXR   Chest X Radiograph 
DLCO  Diffusing capacity of the Lung for Carbon Monoxide  
ECM   Extracellular Matrix 
EMT   Epithelial–Mesenchymal Transition 
FGF-2   Fibroblast Growth Factor 2 
FRAT/GBP Frequently Rearranged in advanced T-cell lymphomas/GSK-3 binding 
protein 
FVC    Forced Vital Capacity  
FXA   Activated Factor X 
GSK-3   Glycogen Synthase Kinase 3 
HP-NAP  Neutrophil-activating protein of Helicobacter pylori 
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HRCT  High Resolution Chest Radiography 
IFN-γ    Interferon γ 
i.p.   Intraperitoneally 
i.v.   Intravenously 
IIPs   Idiopathic Interstitial Pneumonias 
ILDs   Interstitial Lung Diseases 
IPF    Idiopathic Pulmonary Fibrosis 
MAPK  Mitogen-Activated Protein kinase 
MMPs  Matrix Metallo Proteinases 
LPS   bacterial Lipopolysaccharides 
PAH   Pulmonary Arterial Hypertension 
PAI-1, PAI-2  Plasminogen Activator 
PH   Pulmonary hypertension 
P(I)3K/Akt  Phosphatidylinositol 3-Kinase 
PGE2   Prostaglandin E2 
PDGF   Platelet-Derived Growth Factor 
PKA   Protein Kinase A 
PKC   Protein Kinase C 
STAT   Signal Transducer and Activator of Transcription protein 
TGF- β  Transforming Growth Factor- β 
TLRs   Toll like receptors 
TDZD   Thiadiazolidinones 
TIMPs  Tissue Inhibitors of Metallo Proteinases;  
TNF-α  Tumor Necrosis Factor-α  
VEGF   Vascular Endothelial Growth Factor 
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ABSTRACT 
 
Introduction: Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by an 
aberrant interstitial deposition of collagen in the lung parenchyma, leading to progressive lung 
function impairment. Repeated injuries to the alveolar epithelium are believed to lead to an 
imbalance of the extracellular matrix (ECM) turnover supported by metalloproteinases (MMPs) 
and their tissue inhibitors (TIMPs). The kinase GSK-3 is a mediator of the cytokine homeostasis 
and favors the production of pro-inflammatory mediators. Its specific inhibitor, SB216763, 
displayed anti-inflammatory and anti-fibrotic properties of in a mouse model of Bleomycine 
(BLM)-induced pulmonary fibrosis. Furthermore, GSK-3 seems to be involved in the epithelial to 
mesenchimal transition (EMT). The purpose of this study was to assess the expression of MMP9, 
TIMP1, MMP2 and and TIMP2 in the early inflammatory response and in the late fibrosis 
induced by BLM in a mouse model of pulmonary fibrosis. Next goal was to elucidate whether the 
in vivo treatment with SB216763 could modulate MMPs activity and their balance with TIMPs. 
Moreover, in vitro experiments were aimed to identify the signal pathways through which GSK-3 
can modulate MMPs and TIMPs. 
Methods: Cohorts of C57BL6 mice (12 weeks old) were randomized to receive intratracheal 
instillation of either saline (PBS), or BLM alone, or BLM in association with SB216763. The 
inhibitor was administered intraperitoneally the day after BLM and every 48 hours up to the 
sacrifice on day 7 (inflammatory phase) or 28 (fibrotic phase), when bronchoalveolar lavage 
(BAL) was performed and lungs harvested. MMP9 and MMP2 activity was measured by gel 
zymography in BAL fluid (BALF). MMPs and TIMPs expression levels were evaluated by Real 
Time-PCR and Western Blotting. Their tissue localization was evaluated by IHC analysis. In 
vitro experiments were performed using A549 cells as epithelial model, assessing expression and 
activity of MMPs downstream of TNFα, with and without GSK-3 silencing by siRNA. 
Results: MMP9 and MMP2 levels were elevated in BALF from BLM-treated mice at day 7. 
At this time point, the inflammatory cells recruited in the intra-alveolar spaces were alveolar 
macrophages (AMs), lymphocytes and neutrophils. Furthermore, the lung IHC staining indicated 
a strong positivity for MMP9, MMP2, TIMP1 and TIMP2 in interstitial AM (iAM) and, 
specifically, in injured and cuboidalized epithelium. BLM-treated mice sacrificed at day 28 
presented high levels of MMP2 and TIMP1 and low levels of MMP9 in the BALF. Interestingly, 
in vivo GSK-3 inhibition reduced MMP9, MMP2 and TIMP1 levels in the BALF and their 
positivity in iAMs and in epithelium. Moreover, in vitro experiments performed with A549 cells, 
as epithelial model, demonstrated that GSK-3α and GSK-3β silencing increased MMP9 
expression after stimulation with the pro-inflammatory cytokine TNFα. This effect was achieved 
by the interaction of GSK-3 with NF-kB and ERK signalling transduction pathway. 
Conclusions: Our mouse model of BLM-induced pulmonary fibrosis clearly showed an 
imbalance between MMPs and TIMPs during inflammation and fibrosis. Importantly, we 
proposed GSK-3 as a crucial mediator of their expression in AMs and in damaged epithelium. 
Next, in vitro results with A549 cells suggested that GSK-3 silencing induce MMP-9 secretion, 
downstream of TNFα, in a p65-mediated and ERK1,2 dependent manner.  
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RIASSUNTO 
Introduzione: La fibrosi polmonare idiopatica (IPF) è un'interstiziopatia caratterizzata da un 
decorso fatalmente progressivo, che conduce alla completa compromissione della funzione 
polmonare. Pur essendo la sua patogenesi non pienamente compresa, il primum movens sembra 
essere un danno epiteliale ripetuto che induce l'aberrante deposizione di matrice extracellulare 
(ECM), il cui turnover non viene più garantito da metalloproteasi (MMPs) e loro inibitori tissutali 
(TIMPs). La chinasi GSK-3 è nota per il suo ruolo cardine nella modulazione di citochine pro-
infiammatorie ed in diverse vie del segnale e processi cellulari verosimilmente coinvolti nella 
patogenesi della IPF. La sua inibizione in vivo, in un modello murino di fibrosi polmonare 
indotta da bleomicina (BLM), si è dimostrata in grado di modulare sia la risposta infiammatoria 
precoce che la fase fibrotica tardiva. Il ruolo della chinasi nella modulazione dell'equilibrio fra 
MMPs e TIMPs nella fibrogenesi polmonare non è ad oggi chiarito.  
Metodi: Diverse coorti di topi C57BL6 sono state sottoposte all'instillazione endotracheale di 
BLM o PBS e trattate o meno, per via intraperitoneale, con l'inibitore di GSK-3 SB216763. Per 
misurare attività, espressione proteica e genica delle MMPs sono stati utilizzati, rispettivamente, 
zimografia, WB analysis e RT-PCR del liquido di lavaggio bronco alveolare (BALF) di topi 
sacrificati a 7 o 28 giorni dalla somministrazione di BLM. L'espressione proteica e genica delle 
TIMPs è stata valutata con WB e RT-PCR. E' stata inoltre eseguita l'analisi istologica ed 
immunoistochimica dei polmoni, ai due intervalli di tempo. L'effetto in vitro del silenziamento di 
GSK-3 è stato infine studiato su una linea di cellule epiteliali alveolari umane (A549).  
Risultati: Il trattamento con BLM ha dimostrato di aumentare la cellularità ed i livelli di MMP2 e 
MMP9 nel BALF al giorno +7. Si è inoltre registrato un significativo aumento dell'espressione di 
MMP2, MMP9, TIMP1 e TIMP2, all'analisi immunoistochimica, a livello di macrofagi alveolari 
(iAMs) e cellule epiteliali alveolari cuboidalizzate (CEACs). I topi sacrificati al giorno +28 
hanno mostrato un incremento dei livelli di MMP2 e TIMP1, ma non di MMP9, nel BALF. 
L'inibizione in vivo di GSK-3 mediante SB216763 si è dimostra in grado di ridurre il 
reclutamento di cellule infiammatorie e la secrezione di MMPs al giorno +7, a livello del BALF; 
ha inoltre ridotto i livelli di MMP2 al giorno +28. Anche l'espressione di MMPs e TIMPs è stata 
modulata dall'inibizione di GSK-3, a livello di iAMs e CEACs, ad entrambi gli intervalli di 
tempo. Gli esperimenti in vitro su A549 hanno invece dimostrato che il silenziamento di GSK-3 è 
in grado di potenziare la secrezione di MMP9 indotta dallo stimolo proinflammatorio con TNFa, 
che attiva la via di NF-kB.  
Conclusioni: Il nostro lavoro dimostra un ruolo di GSK-3 nella modulazione dell'espressione di 
MMPs e TIMPs in un modello murino di fibrosi polmonare indotta da BLM, che interessa sia la 
fase infiammatoria precoce che quella fibrotica tardiva. L'effetto dell'inibizione di GSK-3 sembra 
esplicarsi, in particolare, a livello di iAMs e CEACs. I dati in vitro, pur preliminari, indicano un 
effetto opposto del silenziamento di GSK-3 sulla secrezione di MMP9 in una linea di cellule 
epiteliali alveolari (A549); il silenziamento di GSK-3 potenzia l’effetto di TNFα sulla secrezione 
di MMP-9, tramite un meccanismo che coinvolge p65 ed è ERK1,2-dipendente  
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1. INTRODUCTION 
 
1.1 Idiopathic Pulmonary Fibrosis 
 
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by an extensive 
lung parenchyma remodelling involving the abnormal deposition of the extracellular matrix 
(ECM) by fibroblasts and the migration of epithelial cells and myofibroblasts through the 
disrupted basement membrane (BM) into the alveolar spaces [1]. The incidence and prevalence 
of IPF are difficult to determine because diagnostic criteria are evolving over time [2] (Table 1). 
The available data demonstrate that IPF favours no particular race, ethnic group or social 
environment. It is estimated that IPF effects at least 5 million persons worldwide, with an 
incidence of approximately 10.7 per 100,000 persons for men and 7.4 per 100,000 persons for 
women [3, 4]. The incidence increases with age. Most commonly the symptoms appear between 
the fifth and the seventh decades of life, with two-thirds of all cases arising in patients over 60 
years of age; mean age at presentation is 66 [5]. Due to the last update of diagnostic criteria, 
allowing diagnosis based on High Resolution Computed Tomography (HRCT) pattern and 
clinical feature, even without a lung biopsy showing a Usual Interstitial Pneumonia (UIP) pattern, 
IPF incidence is likely to increase over the next few years. 
Although idiopathic pulmonary fibrosis is, by definition, a disease of unknown etiology, a 
number of potential risk factors have been described. Smoking is strongly associated with IPF, 
particularly for individuals with a smoking history of more than 20 pack-years. Environmental 
exposure to metal dusts, chemicals, stonecutting, vegetable and animal dusts (e.g. farming) have 
been associated with IPF, as long as microbial agents and gastro-esophageal reflux. Genetic 
factors have also been implied in the pathogenesis or at least associated to the disease, both in 
sporadic and familial forms of IPF. Genetic susceptibility involves, for example, mutations 
expressed in the alveolar epithelial cells including mutations in surfactant proteins A and C [6] 
and the genes encoding the components of telomerase (TERT/TERC), leading to shortened 
telomeres [7]. 
Familial cohorts of IPF (two or more verified cases within a group of relatives belonging to a 
primary family unit) are described, though sporadic cases constitute the majority of disease. 
Clinical features of familial IPF are indistinguishable from those of sporadic form, excepting for 
an earlier age of onset and the appearance of different patterns of gene transcription[8]. Familial 
IPF accounts for less than 5% of all cases of IPF; notably, IIPs other than IPF have been 
identified in unaffected members of  those families[9]. 
 
According to the last ATS/ERS guidelines [2], the diagnosis of IPF requires the following:  
1. Exclusion of other known causes of ILD (e.g., domestic and occupational environmental 
exposures, connective tissue disease, and drug toxicity).   
2. The presence of a UIP pattern on HRCT in patients not subjected to surgical lung biopsy 
(see Table 1).  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3. Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to 
surgical lung biopsy (Table 2 and 3).   
 
Table 1. High-Resolution Computed Tomography criteria for UIP pattern. Modified from [2] 
 
Table 2. Histopathological criteria for UIP pattern (*) Can be associated with acute exacerbation of idiopathic 
pulmonary fibrosis.   (†) An isolated or occasional granuloma and/or a mild component of organizing pneumonia 
pattern may rarely be coexisting in lung biopsies with an otherwise UIP pattern.   (‡) This scenario usually represents 
end-stage fibrotic lung disease where honeycombed segments have been sampled but where a UIP pattern might be 
present in other areas. Such areas are usually represented by overt honeycombing on HRCT and can be avoided by 
pre-operative targeting of biopsy sites away from these areas using HRCT. Modified from [2]. 
 
 
 
vestigating other mutations, associations, and gene–environment
relationships are needed. In our present state of understand-
ing, the committee does not recommend genetic testing in
patients with either familial or sporadic IPF as part of clinical
evaluation.
DEFINITION OF UIP PATTERN
UIP Pattern: HRCT Features
HRCT is an essential component of the diagnostic pathway in
IPF (Table 4, Figure 1). The optimal HRCT technique for
evaluation of ILD is provided in the online supplement (see
Table E6). UIP is characterized on HRCT by the presence of
reticular opacities, often associated with traction bronchiectasis
(98, 99). Honeycombing is common, and is critical for making
a definite diagnosis. Honeycombing is manifested on HRCT as
clustered cystic airspaces, typically of comparable diameters on
the order of 3–10 mm but occasionally as large as 2.5 cm. It is
usually subpleural and is characterized by well-defined walls
(100). Ground glass opacities are common, but usually less
extensive than the reticulation. The distribution of UIP on
HRCT is characteristically basal and peripheral, though often
patchy. The presence of coexistent pleural abnormalities (e.g.,
pleural plaques, calcifications, significant pleural effusion) sug-
gests an alternative etiology for UIP pattern. Micronodules, air
trapping, nonhoneycomb cysts, extensive ground glass opacities,
consolidation, or a peribronchovascular-predominant distribu-
tion should lead to consideration of an alternative diagnosis.
Mild mediastinal lymph node enlargement (usually , 1.5 cm
in short axis) can be seen (101, 102). The chest radiograph is
less useful than HRCT in evaluating patients with suspected
IPF (103).
Several studies have documented that the positive predictive
value of a HRCT diagnosis of UIP is 90 to 100% (103–108). These
studies are affected by selection bias because they only included
patients with biopsy-proven diagnoses. Nonetheless, a UIP pat-
tern on HRCT is highly accurate for the presence of UIP pattern
on surgical lung biopsy. If honeycombing is absent, but the
imaging features otherwise meet criteria for UIP, the imaging
features are regarded as representing possible UIP, and surgical
lung biopsy is necessary to make a definitive diagnosis. In patients
whose HRCT does not demonstrate a UIP pattern, the surgical
lung biopsy may s ill demonstrate UIP pattern on histopathology.
TABLE 4. HIGH-RESOLUTION COMPUTED TOMOGRAPHY CRITERIA FOR UIP PATTERN
UIP Pattern (All Four Features) Possible UIP Pattern (All Three Features) Inconsistent with UIP Pattern (Any of the Seven Features)
d Subpleural, basal predominance
d Reticular abnormality
d Honeycombing with or without traction
bronchiectasis
d Absence of features listed as inconsistent with
UIP pattern (see third column)
d Subpleural, basal predominance
d Reticular abnormality
d Absence of features listed as inconsistent with
UIP pattern (see third column)
d Upper or mid-lung predominance
d Peribronchovascular predominance
d Extensive ground glass abnormality (extent .
reticular abnormality)
d Profuse micronodules (bilateral, predominantly
upper lobes)
d Discrete cysts (multiple, bilateral, away from areas
of honeycombing)
d Diffuse mosaic attenuation/air-trapping (bilateral,
in three or more lobes)
d Consolidation in bronchopulmonary segment(s)/lobe(s)
Definition of abbreviation: UIP 5 usual interstitial pneumonia.
Figure 1. High-resolution com-
puted tomography (HRCT) im-
ages demonstrating usual
interstitial pneumonia (UIP)
pattern and possible UIP pat-
tern. (A and B) UIP pattern,
with extensive honeycomb-
ing: axial and coronal HRCT
images show basal predomi-
nant, peripheral predominant
reticular abnormality with
multiple layers of honeycomb-
ing (arrows). (C and D) UIP
pattern, with less severe hon-
eycombing: axial and coronal
CT images show basal pre-
dominant, peripheral predom-
inant reticular abnormality
with subpleural honeycomb-
ing (arrows). (E and F ) Possible
UP pattern: axial and coronal
images show peripheral pre-
dominant, basal predominant
reticular abnormality with
a moderate amount of ground
glass abnormality, but without
honeycombing.
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UIP Pattern: Histopathology Features
The histopathologic hallmark and chief diagnostic criterion is
a heterogeneous appearance at low magnification in which areas
of fibrosis with scarring and honeycomb change alternate with
areas of less affected or normal parenchyma (1, 12) (Table 5,
Figure 2). These histopathologic changes often affect the
subpleural and paraseptal parenchyma most severely. Inflam-
mation is usually mild and consists of a patchy interstitial
infiltrate of lymphocytes and plasma cells associated with
hyperplasia of type 2 pneumocytes and bronchiolar epithelium.
The fibrotic zones are composed mainly of dense collagen,
although scattered convex subepithelial foci of proliferating
fibroblasts and myofibroblasts (so-called fibroblast foci) are
a consistent finding. Areas of honeycomb change are composed
of cystic fibrotic airspaces that are frequently lined by bronchi-
olar epithelium and filled with mucus and inflammatory cells.
Smooth muscle metaplasia in the interstitium is commonly seen
in areas of fibrosis and honeycomb change.
The differential diagnosis for UIP pattern on pathology is
relatively short, especially when strict criteria for UIP are
maintained. The major differential diagnostic considerations
include UIP in other clinical settings such as connective tissue
diseases, chronic hypersensitivity pneumonitis (extrinsic allergic
alveolitis), and pneumoconioses (especially asbestosis).
Some biopsies may reveal a pattern of fibrosis that does not
meet the above criteria for UIP pattern (1). These biopsies may
be termed ‘‘nonclassifiable fibrosis.’’ In the absence of histologic
features diagnostic of an alternative condition (e.g., hypersen-
sitivity pneumonitis, sarcoidosis, etc.), such biopsies may be
consistent with the diagnosis of IPF (Tables 5 and 6) in the
appropriate clinical and radiologic setting and after careful
multidisciplinary discussion.
DIAGNOSIS
Diagnostic criteria and schema for adult patients with ILD and
suspected IPF are presented in Figure 3 and Table 6. Careful
exclusion of alternative etiologies through multidisciplinary dis-
cussion between pulmonologists, radiologists, and pathologists
experienced in the diagnosis of ILD is of the utmost importance
to an accurate diagnosis. In situations in which multidisciplinary
discussion is not feasible, it is recommended that patients be
referred to experienced clinical experts in ILD for consultation.
The diagnostic criteria for IPF presented in this document
have been significantly modified from those stated in the
previous ATS/ERS Statement (1). Given the high-quality
evidence regarding HRCT specificity for the recognition of
histopathologic UIP pattern, surgical lung biopsy is not essential
(104, 105, 109, 110). In the appropriate clinical setting (as
described in the clinical presentation section above; this in-
cludes a thorough medical, occupational/environmental and
family history, physical examination, physiological testing, and
laboratory evaluation), the presence of a UIP pattern on HRCT
is sufficient for the diagnosis of IPF. Thus, th maj r and minor
criteria for the clinical (i.e., nonpathologic) diagnosis of IPF
have been eliminated.
Diagnostic Criteria
The diagnosis of IPF requires the following:
1. Exclusion of other known causes of ILD (e.g., do estic
and occupational environmental exposures, connective
tissue disease, and drug toxicity).
2. The presence of a UIP pattern HRCT in patients not
subjected to surgical lung biopsy (see Table 4).
3. Specific combinations of HRCT and surgical lung biopsy
pattern in patients subjected to surgical lung biopsy (see
Tables 5 and 6).
Thus, the accuracy of diagnosis of IPF increases with clinical,
radiologic, and histopathologic correlation and can be accom-
plished with a multidisciplinary discussion among experienced
clinical experts in the field of ILDs (111). This is particularly
relevant in cases in which the radiologic and histopathologic
patterns are discordant (e.g., HRCT is inconsistent with UIP and
histopathology is UIP). An HRCT or pathologic UIP pattern is
not 100% specific to IPF (1, 12, 112–114). Discordant histologic
patterns on surgical lung biopsy specimens obtained from
different segments have been described. Cases with coexisting
UIP pattern and fibrotic NSIP pattern (discordant UIP) appear
to behave similarly to those with UIP pattern in all lobes
(concordant UIP) (115, 116). This supports the obtainment of
TABLE 5. HISTOPATHOLOGICAL CRITERIA FOR UIP PATTERN
UIP Pattern (All Four Criteria) Probable UIP Pattern
Possible UIP Pattern
(All T ree Criteria)
Not UIP Pattern
(Any of the Six Criteria)
d Evidence of marked fibrosis/
architectural distortion, 6
honeycombing in a
predominantly subpleural/
paraseptal distribution
d Presence of patchy
involvement of lung
parenchyma by fibrosis
d Presence of fibroblast foci
d Absence of features
against a diagnosis
of UIP suggesting
an alternate diagnosis
(see fourth column)
d Evidence of marked fibrosis /
architectural distortion, 6
honeycombing
d Absence of either patchy
involvement or fibroblastic
foci, but not both
d Absence of features against a
diagnosis of UIP suggesting
an alternate diagnosis
(see fourth column)
OR
d Honeycomb changes only‡
d Patchy or diffuse
involvement of lung
parenchyma by
fibrosis, with or without
interstitial inflammation
d Absence of other criteria
for UIP (see UIP
PATTERN column)
d Absence of features
against a diagnosis
of UIP suggesting an
alternate diagnosis
(see fourth column)
d Hyaline membranes*
d Organizing pneumonia*†
d Granulomas†
d Marked interstitial
inflammatory cell
infiltrate away from
honeycombing
d Predominant airway
centered changes
d Other features
suggestive of an
alternate diagnosis
Definition of abbreviations: HRCT 5 high-resolution computed tomography; UIP 5 usual interstitial pneumonia.
* Can be associated with acute exacerbation of idiopathic pumonary fibrosis.
† An isolated or occasional granuloma and/or a mild component of organizing pneumonia pattern may rarely be coexisting in lung biopsies with an otherwise UIP
pa t rn.
‡ This scenario usually represents end-stage fibrotic lung disease where honeycombed segments have been sampled but where a UIP pattern might be present in other
areas. Such areas are usually represented by overt honeycombing on HRCT and can be avoided by pre-operative targeting of biopsy sites away from these areas using HRCT.
American Thoracic Society Documents 795
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Table 3. Combination of HRCT and surgical lung biopsy for the diagnosis of IPF (requires multidisciplinary 
discussion). Bold type indicates combinations of HRCT and surgical lung biopsy patterns that correspond with a 
diagnosis of IPF. (*) Patterns as described in Tables 1 and 2. (‡) Nonclassifiable fibrosis: some biopsies may reveal a 
pattern of fibrosis that does not meet the criteria for UIP pattern and the other IIPs. These biopsies may be termed 
‘‘nonclassifiable fibrosis.’’ (†) The accuracy of the diagnosis of IPF increases with multidisciplinary discussion 
(MDD). This is particularly relevant in cases in which the radiologic and histopathologic patterns are discordant. 
Data suggest that the accuracy of diagnosis is improved with MDD among interstitial lung disease experts; timely 
referral to interstitial lung disease experts is encouraged. MDD include discussions of the potential for sampling error 
and a re-evaluation of adequacy of technique of HRCT. Modified from [2]. 
 
1.1.1 Definition of UIP pattern  
UIP Pattern: HRCT Features  
HRCT is an essential component of the diagnostic pathway in IPF (Table 4, Figure 1). UIP is 
characterized on HRCT by the presence of reticular opacities, often associated with traction 
bronchiectasis. Honeycombing is common, and is critical for making a definite diagnosis. 
Honeycombing is manifested on HRCT as clustered cystic airspaces, typically of comparable 
diameters on the order of 3–10 mm but occasionally as large as 2.5 cm. It is usually subpleural 
and is characterized by well-defined walls. Ground glass opacities are common, but usually less 
extensive than the reticulation. The distribution of UIP on HRCT is characteristically basal and 
peripheral, though often patchy. The presence of coexistent pleural abnormalities (e.g., pleural 
plaques, calcifications, significant pleural effusion) suggests an alternative etiology for UIP 
pattern. Micronodules, air trapping, nonhoneycomb cysts, extensive ground glass opacities, 
consolidation, or a peribronchovascular-predominant distribution should lead to consideration of 
an alternative diagnosis. Mild mediastinal lymph node enlargement (usually 1.5 cm in short axis) 
can be seen. The chest radiograph is less useful than HRCT in evaluating patients with suspected 
IPF.  
Several studies have documented a great positive predictive value of a HRCT diagnosis of 
UIP. Thus, an UIP pattern on HRCT is highly accurate for the presence of UIP pattern on surgical 
lung biopsy. If honeycombing is absent, but the imaging features otherwise meet criteria for UIP, 
Recommendation: Transbronchial biopsy should not be used
in the evaluation of IPF in the majority of patients, but
may be appropriate in a minority (weak recommendation,
low-quality evidence).
Values: This recommendation places a high value on the addi-
tional morbidity of transbronchial lung biopsy in patients
with IPF who will subsequently undergo surgical lung
biopsy and low value on possible diagnostic specificity.
Remarks: (Vote: none for the use of transbronchial biopsy, 23
against the use of transbronchial biopsy, no abstentions, 8
absent.)
j Question: Should serologic testing for connective tissues
dis ase be used in the evaluation of suspected IPF?
There are no reliable data on the role of screening serologies
in patients with suspected IPF. Connective tissue disease
can present with a UIP pattern (124), and ILD has been
described as t sole clinical manifestation of these
conditions and can precede the overt manifestation of
a specific connective tissue disease (125).
Recommendation: Serologic testing for connective tissue dis-
ease should be performed in the evaluation of IPF in the
majority of patients, but may not be appropriate in a minor-
ity (weak recommendation, very low-quality evidence).
Values: This recommendation places a high value on
distinguishing connective tissue disease from IPF and
low value on cost.
Remarks: Serologic evaluation should be performed even in
the absence of signs or symptoms of connective tissue
disease, and should include rheumatoid factor, anti-cyclic
TABLE 6. COMBINATION OF HIGH-RESOLUTION COMPUTED TOMOGRAPHY AND SURGICAL LUNG BIOPSY FOR THE
DIAGNOSIS OF IPF (REQUIRES MULTIDISCIPLINARY DISCUSSION)
HRCT Pattern* Surgical Lung Biopsy Pattern* (When Performed) Diagnosis of IPF?†
UIP UIP YES
Probable UIP
Possible UIP
Nonclassifiable fibrosis‡
Not UIP No
Possible UIP UIP YES
Probable UIP
Possible UIP Probablex
Nonclassifiable fibrosis
Not UIP No
Inconsistent with UIP UIP Possiblex
Probable UIP No
Possible UIP
Nonclassifiable fibrosis
Not UIP
Definition of abbreviations: HRCT 5 high-resolution computed tomography; IPF 5 idiopathic pulmonary fibrosis; UIP 5 usual interstitial pneumonia.
Bold type indicates combinations of HRCT and surgical lung biopsy patterns that correspond with a diagnosis of IPF (a YES in the far right column). The combination of
UIP HRCT and probable UIP or possible UIP or Nonclassifiable fibrosis (surgical lung biopsy patterns) (for example) equals a diagnosis of IPF; the combination of UIP
HRCT and Not UIP (surgical lung biopsy pattern) does not make the diagnosis of IPF.
* Patterns as described in Tables 4 and 5.
‡ Nonclas ifiable fibrosis: Some biopsies may reveal a pattern of fibro is th t does not meet the above criteria for UIP pattern and the ther idiopathic interstitial
pneumonias (1) (see text). These biopsies may be termed ‘‘nonclassifiable fibrosis.’’
† The accuracy of the diagnosis of IPF increases with multidisciplinary discussion (MDD). This is particularly relevant in cases in which the radiologic and histopathologic
patterns are discordant (e.g., HRCT is inconsistent with UIP and histopathology is UIP). There are data to suggest that th accuracy of diagnosis is im roved with MDD among
interstitial lung disease experts compared to clinician-specialists in the community setting (126); timely referral to interstitial lung disease experts is encouraged.
x Multidisciplinary discussion should include discussions of the potential for sampling error and a re-evaluation of adequacy of technique of HRCT. NOTE: In cases with an
‘‘inconsistent with UIP’’ HRCT pattern and a ‘‘UIP’’ surgical lung biopsy pattern, the possibility of a diagnosis of IPF still exists and clarification by MDD among interstitial lung
disease experts is indicated.
Figure 3. Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).
Patients with suspected IPF (i.e., patients with unexplained dyspnea on
exertion and/or cough with evidenc of in erstitial lung disease [ILD])
should be carefully evaluated for identifiable causes of ILD. In the
absence of an identifiable cause for ILD, an HRCT demonstrating UIP
pattern is diagnostic of IPF. In the absence of UIP pattern on HRCT, IPF
can be diagnosed by the combination of specific HRCT and histopath-
ological patterns. The accuracy of the diagnosis of IPF increases with
multidisciplinary discussion (MDD) among ILD experts. *Refer to Table
4 for definitions. †Refer to Table 5 for definitions.
g
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the imaging features are regarded as representing possible UIP, and surgical lung biopsy is 
necessary to make a definitive diagnosis. In patients whose HRCT does not demonstrate a UIP 
pattern, the surgical lung biopsy may still demonstrate UIP pattern on histopathology.  
UIP Pattern: Histopathology Features  
The histopathologic hallmark and chief diagnostic criterion is a heterogeneous appearance at 
low magnification in which areas of fibrosis with scarring and honeycomb change alternate with 
areas of less affected or normal parenchyma (1, 12) (Table 5, Figure 2). These histopathologic 
changes often affect the subpleural and paraseptal parenchyma most severely. Inflammation is 
usually mild and consists of a patchy interstitial infiltrate of lymphocytes and plasma cells 
associated with hyperplasia of type 2 pneumocytes and bronchiolar epithelium. The fibrotic zones 
are composed mainly of dense collagen, although scattered convex subepithelial foci of 
proliferating fibroblasts and myofibroblasts (so-called fibroblast foci) are a consistent finding. 
Areas of honeycomb change are composed of cystic fibrotic airspaces that are frequently lined by 
bronchiolar epithelium and filled with mucus and inflammatory cells. Smooth muscle metaplasia 
in the interstitium is commonly seen in areas of fibrosis and honeycomb change.  
The differential diagnosis for UIP pattern on pathology is relatively short, especially when strict 
criteria for UIP are maintained. The major differential diagnostic considerations include UIP in 
other clinical settings such as connective tissue diseases, chronic hypersensitivity pneumonitis 
(extrinsic allergic alveolitis), and pneumoconioses (especially asbestosis).  Some biopsies may 
reveal a pattern of fibrosis that does not meet the above criteria for UIP pattern. These biopsies 
may be termed ‘‘nonclassifiable fibrosis.’’ In the absence of histologic features diagnostic of an 
alternative condition (e.g., hypersensitivity pneumonitis, sarcoidosis, etc.), such biopsies may be 
consistent with the diagnosis of IPF (Tables 2 and 3) in the appropriate clinical and radiologic 
setting and after careful multidisciplinary discussion.  
 
1.1.2 Clinical picture 
 
The natural course of IPF is characterized by a progressive decline in subjective and objective 
pulmonary function until eventual death from respiratory failure or complicating comorbidity. 
Available longitudinal studies do not allow a clear assessment of median survival. Retrospective 
longitudinal studies suggest a median survival time from 2 to 3 years since diagnosis but recent 
data from prospective studies suggest that this may be an underestimate [10].  
Symptoms such as weight loss, fever, and athralgias are unusual in IPF, whereas gastro-
oesophageal acid reflux is present in close to 90% of patients, but often occurs without symptoms 
[11]. Auscultation of the lungs reveals early bibasal inspiratory crackles, known as Velcro 
crackles. Clubbing is found in approximately 50% of patients. There are no other physical 
manifestations, unless cor pulmonale has developed in association with end-stage disease. There 
are no specific laboratory abnormalities. Noteworthy pulmonary hypertension has been reported 
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to occur in 32 to 84% of patients with IPF. The exact prevalence remains unclear because triggers 
for the evaluation of pulmonary pressures and the best method to detect pulmonary hypertension 
in IPF remain unsettled [12]. Diffusion capacity is strongly correlated with pulmonary 
hypertension, being inversely related [13, 14]. However, the severity of restrictive physiology has 
little bearing on the prevalence or degree of pulmonary hypertension. Several studies have 
demonstrated a lack of correlation between pulmonary artery pressure and forced vital capacity 
(FVC) [13-15]. Right-heart catheterization is the best diagnostic test for pulmonary hypertension 
but the implementation of such invasive testing is difficult to justify in the absence of data 
demonstrating a benefit to treatment of pulmonary hypertension in IPF. Still it is clear that the 
presence of pulmonary hypertension in IPF adversely affects survival [16]. 
There appear to be several possible natural histories for patients with IPF (Figure 1). For a single 
patient, the natural history is unpredictable at the time of the diagnosis. The majority of patients 
demonstrate a slow, gradual progression over years. Some patients remain stable while others 
have an accelerated decline. Some may experience episodes of acute respiratory worsening. It is 
unknown if these different natural histories represent distinct phenotypes of IPF or if the natural 
history is influenced by geographic, ethnic, cultural, racial, or other factors. Other comorbid 
conditions such as emphysema and pulmonary hypertension may impact the disease course [13].  
 
Figure 1. Natural history of IPF. Modified from [2]  
1.1.3 Treatment 
In terms of disease management, steroids, N-acetylcysteine (NAC), Azathioprine have been used 
for many years without any evidence of efficacy, whilst lung transplantation have been the only 
effective treatment until 2012. Over the last 3 year 2 different drugs, Pirfenidone [17] and 
Nintedanib [18], have been shown to slower disease progression in multicentric placebo 
controlled clinical trials and another trial showed an increased risk of mortality associated with 
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triple therapy (NAC + Azathioprine + Prednisone), if compared to placebo [19]. Currently, 
Pirfenidone and Nintedanib are the only drugs approved for IPF treatment and lung 
transplantation is still the unique strategy that has been shown to improve survival in IPF 
patients. 
 
 
1.1.4 Pathogenesis 
 
Although IPF etiology is, by definition, still unknown, many different mechanisms and 
pathways have been shown to be involved, with different degree of evidence, in the pathogenesis 
of this disease. 
The primum movens is believed to be a persistent epithelial injury which, in genetically 
susceptible individuals, turns into extensive epithelial regeneration, reactivation of developmental 
pathways and uncontrolled fibroproliferation due to disturbed epithelial–mesenchymal crosstalk; 
this results in progressive scarring of the lung [6, 20, 21]. The disturbed epithelial–mesenchymal 
crosstalk involves: increased generation of fibrogenic mediators by the epithelium, including the 
tissue factor/factor VIIa–factor X complex, transforming growth factor (TGF)-β, platelet-derived 
growth factor (PDGF) and connective tissue growth factor [20, 22]; the loss of control of 
fibroblasts via reduced epithelial prostaglandin E2/urokinase plasminogen activator [23]; and the 
upregulation of developmental pathways such as Wnt and Notch [20, 21, 24], which may act in a 
paracrine fashion on the parenchyma [25].  
IPF is characterized by an extensive lung parenchyma remodeling involving the abnormal 
deposition of the extracellular matrix (ECM) by fibroblasts and the migration of epithelial cells 
and myofibroblasts through the disrupted basement membrane (BM) into the alveolar spaces [1]. 
Within the histologic picture of UIP, fibroblastic foci are areas of myofibroblast proliferation 
thought to be the main site of ECM deposition. ECM-producing lung fibroblasts are the key 
source of this deposition; however, these cells are heterogeneous in a number of phenotypic 
features [26]. 
 Recent investigations have provided support for the hypothesis that they arise from several 
sources, including: 
- resident pulmonary fibroblasts,   
- bone marrow-derived circulating fibrocytes that infiltrate the lungs, via the gradient 
formed by the chemokine stromal cell-derived factor-1–CXCR4 axis [20]; 
- alveolar epithelial cells through a process called epithelial-mesenchymal transition (EMT) 
[27];  
- transcription factor Foxd1 progenitor-derived pericytes, whcich may be an important 
precursor of lung myofibroblasts [28]. 
 
Several growth factors are suggested to be pivotal in the development of IPF, including platelet-
derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and vascular endothelial 
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growth factor (VEGF). PDGF is a fibrogenic mediator [29], and was increased in a murine IPF-
animal model [30]. The inhibition of PDGF signalling reduced bleomycin-induced pulmonary 
fibrosis in mice [31]. bFGF is a potent mitogenic factor and high levels of bFGF were found in 
lung tissue derived from patients with IPF [32]. And finally, blocking VEGF signalling reduced 
lung fibrosis in a mouse model [33].  
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Figure 2. Pathogenesis of IPF. Chronic apithelial  injury is believed to induce impaired ECM turnover and aberrant 
finrotic response, sustained by many different pathways. Balance between MMPs and TIMPs seems to play a crucial 
role in this process.  
 
Nintedanib is an orally available indolinone derivate that competitively binds to the ATP-binding 
sites within the kinase domains of VEGF receptor (VEGFR)1, VEGFR2, VEGFR3, FGF receptor 
(FGFR)1, FGFR3, and PDGF receptor (PDGFR)α and PDGFRβ [34].  
Pirfenidone is an orally available drug that exhibits anti-fibrotic and anti-inflammatory properties 
in vitro and in vivo. There is evidence to show that pirfenidone diminishes fibroblast 
proliferation, secretion of the fibrosis-associated proteins and cytokines, biosynthesis and 
accumulation of extracellular matrix as well as accumulation of inflammatory cells and tumour 
necrosis factor-α synthesis [35].  
The exact anti-fibrotic mechanism of action is less characterized, for pirfenidone if compared 
with Nintedanib. However, further in vitro and in vivo studies are ongoing for both drugs, in 
order to better understand their full anti-fibrotic potential and their specific effect on each pro-
fibrotic pathway, this way improving the comprehension of IPF pathogenesis. 
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1.1.5 Matrix Metalloproteases (MMPs) and their Tissue Inhibitors (TIMPs) 
 
The aberrant deposition of ECM is a hallmark of IPF. In this context, matrix metalloproteinases 
(MMPs), a family of extracellular and Zinc-dependent enzymes, play a crucial role because of 
their proteolytic activity against many components of ECM, including interstitial collagens, BM 
collagen (type IV), fibronectin, laminin and various proteoglycans (J.F. Woessner, FASEB, 
1991). MMPs activity is regulated at multiple levels including gene transcription, 
compartimentalization, extracellular activation of the zymogen and inactivation by specific 
inhibitors referred to as tissue inhibitors of metalloproteinases (TIMPs) [36]. Accumulating 
evidence indicates that an imbalance between MMPs and TIMPs may lead to the alteration of the 
ECM metabolism in a variety of pulmonary disorders including IPF [37, 38], emphysema [39], 
asthma [40, 41] and lung carcinoma [42]. Moreover, MMPs activity in ECM remodeling has been 
shown to be crucial in local and metastatic cancer invasiveness [43]. 
Studies from different groups have shown that some MMPs such as MMP-1, MMP-2, MMP-3, 
MMP-7, MMP-9, and MMP-13 are highly expressed in IPF, playing diverse roles in the fibrotic 
response; however, the exact mechanisms are not well characterized [38, 44-46]. Recently, it has 
been identified the overexpression of MMP-19 in the hyperplastic alveolar epithelium of IPF 
lungs and demonstrated that, surprisingly, mice lacking this MMP developed an exacerbated 
bleomycin-induced lung fibrosis [47]. The gelatinases (MMP-2 and -9) and, in particular, MMP-
7, have already been suggested to play a role in human and experimental lung fibrosis, thus 
underscoring the dynamic regulation of the ECM and of remodelling processes in the lung [48]; 
MMP-1 is lacking in rodents, and, hence, MMP-13 (also known as collagenase-3) is the principal 
interstitial collagenase in this species and has a high specificity for degrading insoluble fibrillar 
collagens, especially type II and I collagens [49-51]. The expression of MMP-8 and -13 was 
shown to be down-regulated in a model of pulmonary fibrosis induced in rats with paraquat and 
hyperoxia [52]. A recent study performed on human lung tissues from patients with sporadic IPF 
identified MMP-7 and the collagenases MMP-1 and MMP-13 as key MMPs upregulated in 
human IPF. In a murine model of bleomycin-induced lung fibrosis, in response to bleomycin 
challenge and compared with wild-type (WT) mice, MMP-13-/- mice exhibited an increased 
inflammatory reaction and a greater extent of fibrosis, thus pointing at MMP-13 as a key factor in 
the regulation of ECM turnover and collagen deposition in both mice and man [38]. 
We focused our study on two gelatinases, MMP-9 (gelatinase B) and MMP-2 (gelatinase A) that 
are able to degrade the common substrates type IV collagen, the major constituent of the BM, 
type V collagen and gelatin. MMPs are secreted as inactive precursors which have to be activated 
in the extracellular space. MMP-2 can be activated by type I collagen and thrombin [53, 54], but 
also by a membrane-type MMP-dependent pathway involving TIMP-2 [55].  An imbalance 
between MMPs and TIMPs might be involved in the accumulation of ECM in fibrogenesis [56]. 
Accordingly, a greater increase in the levels of TIMP than levels of MMP-2 was reported and 
such an imbalance would favour the enhanced deposition of ECM proteins [45]. Interestingly, 
TGF-β induced lung fibrosis in mice was primarily due to TIMP up-regulation [57], and a recent 
study demonstrated that over expression of MMP-9 by alveolar macrophages in mice attenuated 
the fibrotic reaction after bleomycin instillation [58]. Interestingly, it has been showed that 
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Nintedanib can up-regulate pro-MMP-2 secretion, but down-regulated its inhibitor TIMP-2 in 
primary lung fibroblasts from IPF patients. Only minor amounts of pro-MMP-9 were detected in 
those cells [34]. 
These two gelatinases, MMP-2 and MMP-9, differ greatly in transcription control being 
MMP-2 constitutively expressed and MMP-9 induced by soluble factors such as cytokines and 
growth factors and by integrin-mediated signalling through cell-matrix or cell-cell interactions 
[36]. The property of being induced has made MMP-9 an interesting target of study in many 
pathological conditions including IPF [59]. In healthy lung, indeed, MMP-9 secretion is usually 
low or absent but, under stimulation, bronchial epithelial cells, Clara cells, alveolar type II cells, 
fibroblasts, smooth muscle cells and endothelial cells can produce it. Among inflammatory cells, 
alveolar macrophages, eosinophils, mast cells, lymphocytes, NK cells and dendritic cells, all can 
produce MMP-9 but, the neutrophil represents the main source of MMP-9 which is synthesized 
during cell maturation in the bone marrow and then, stored in specific granules from which it is 
readily released. Moreover, the neutrophil does not secrete MMP-9 in complex with TIMP-1 as 
many cells do, but can secrete it either alone or in a covalent complex with NGAL [60]. Despite 
the large number of studies, the role of MMP-9 in the lung is still not completely understood. In 
vitro studies of wound repair of human respiratory epithelium demonstrated that MMP-9 is 
implicated in epithelial cell migration [61]. Another study employing mouse model of lung injury 
carried out with intratracheal instillation of bleomycin (BLM) demonstrated that MMP-9 is 
required for alveolar bronchiolization, by facilitating migration of Clara cells and other 
bronchiolar cells into the region of alveolar injury [39].   
 
 
1.2 GSK-3 
 
The serine-threonine kinase GSK-3 was initially considered an unconventional and interesting 
kinase because it is constitutively active, its substrates usually need to be pre-phosphorylated by 
another kinase, and it is inhibited, rather than activated, in response to stimulation of the two 
main signalling pathways known to impinge on GSK-3, the insulin and Wnt pathways [62, 63]. 
However, two key developments in particular transformed this perspective to the current state of 
widespread interest: 
- the discovery that GSK-3 is a key kinase contributing to abnormal phosphorylation of the 
microtubule-binding protein tau in the process thought to cause neurofibrillary tangles in 
Alzheimer's disease [64]; this finding underlined GSK-3 as a potential  therapeutic target  in 
this disease; 
- the finding that GSK-3 is inhibited by lithium [65], the classical mood stabilizer used in the 
treatment of bipolar disorder This finding not only raised the prospect that GSK-3 may have a 
central role this disorder, but also provided a relatively selective and well tolerated inhibitor 
of GSK-3 that opened the door for discoveries of other targets of GSK-3. Thus, starting from 
a single disorder, the interest in GSK-3 and its actions became widespread, and it now seems 
like GSK-3 touches almost every aspect of cellular signalling and is involved in an 
unparalleled number of disease processes.  
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Following these discoveries and the increasing awareness of new actions of GSK-3, many 
additional inhibitors of GSK-3 were developed, as GSK-3 began to be seriously considered as a 
therapeutic target [66]. Potential therapeutic applications include many prevalent conditions, such 
as cancer, cardiovascular diseases, diabetes, inflammatory conditions, neurodegenerative 
diseases, and psychiatric diseases, as well as other less prevalent conditions. Such an expansive 
influence on cellular signalling and association with multiple disease processes has stimulated to 
inquire how GSK-3 can manage all of its tasks in an organized fashion, and how such a pervasive 
kinase can reasonably be thought of as a feasible therapeutic target. Recent progresses are leading 
to a more complete understanding of this enigmatic kinase and its potential as a therapeutic 
target. Moreover, substantial evidence supports the conclusion that inhibition of GSK-3 is an 
important action contributing to the mood stabilizing action of lithium in bipolar disease, 
demonstrating that in vivo inhibition of GSK-3 is, in fact, feasible for safe therapeutic 
interventions.  
1.2.1 Regulation of glycogen synthase kinase-3-mediated substrate phosphorylation  
GSK-3 exists in two paralogs (homologous proteins derived from different genes) GSK-3α and 
GSK-3β that are commonly referred to as isoforms. A theoretical analysis found that GSK-3β 
has more predicted substrates than any other kinase [67]; about 100 proteins phosphorylated by 
GSK-3 have already been reported [68], and this high number of substrates raises the question of 
how GSK-3 can phosphorylate so many proteins in a cell with any discretion. There must be 
certain characteristics of GSK-3 that are particularly useful and versatile which outweigh the 
functional constraints and complexities required to provide discretion among many substrates. 
Since GSK-3's activity as a kinase is not particularly different from other kinases, there has been 
a suggestion that the mechanisms regulating GSK-3 might be particularly adaptable for 
incorporation into new signalling pathways without perturbing those already existent. Thus, a key 
to GSK-3's actions may be the multiple regulatory mechanisms available to orchestrate its 
substrate-specific actions. However, this promiscuity also appears to have provided multiple 
interactions that can be disrupted to result in unbridled actions of GSK-3 contributing to multiple 
types of diseases. These crucial mechanisms that confer specificity for signalling pathways and 
for substrates have originally been categorized to include the regulatory phosphorylation of GSK-
3 itself, the regulation of substrate availability, the subcellular localization of GSK-3 and its 
substrates, and the incorporation of GSK-3 into protein complexes, categories that remain the 
primary mechanisms known to regulate GSK-3 [69].  
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Figure 3. Serine9-phosphorylation of GSK-3β inhibits its phosphorylation of primed substrates. (A) Representation 
of GSK-3β based on a recently reported crystal structure showing the adjacent kinase domain and primed-substrate 
binding domain [70]. (B) Phosphorylated serine-9 in the N-terminal tail of GSK-3β binds the primed substrate-
binding domain. (C) Primed substrates first associate with the primed substrate-binding domain of GSK-3β, which 
places a Ser/Thr four residues N-terminal to the primed phosphorylated Ser/Thr adjacent to the kinase domain of 
GSK-3β to facilitate substrate phosphorylation. (D) Phosphorylated serine-9 in the N-terminal tail of GSK-3β 
inhibits the association of primed substrates with the primed substrate binding domain of GSK-3β. From (Beurel et 
al. / Pharmacology & Therapeutics 148, 2015) [71].  
1.2.2 Regulatory post-translational modifications of GSK-3  
Inhibitory serine-phosphorylation is the most frequently examined mechanism that regulates the 
activity of GSK-3. Two key functional domains of GSK-3 have been identified (Figure 3), a 
primed-substrate binding domain that recruits substrates to GSK-3, and a kinase domain that 
phosphorylates the substrate [72]. The former domain provides a binding site for most GSK-3 
substrates, those that are primed by being pre-phosphorylated. Although GSK-3 can 
phosphorylate a few non-primed substrates at Ser-Pro sites, the most common target for 
signaling pathways that activate these kinases can inhibit GSK3 by
phosphorylating the inhibitory serines on GSK3. An intriguing excep-
tion to this regulatory mechanism is the recent discovery that GSK3
phosphorylates AMP-activated kinase (AMPK) to inhibit its activity
(Suzuki et al., 2013). Remarkably, Akt, which usually inhibits GSK3
by serine-9/21 phosphorylation, promotes AMPK phosphorylation by
GSK3, showing that in some circumstances Akt and GSK3 cooperatively
modulate signaling pathways. However, in general, measuring the
serine-9/21 phosphorylation of GSK3 provides a valuable assessment
of conditions that regulate the activity of GSK3 via this mechanism,
but it is us ful to consider four caveats to this conclusion.
(i) Not all substrates of GSK3 are primed, so these non-primed sub-
strates may not require binding to the primed substrate binding
domain to be phosphorylated by GSK3, depending on the exis-
tence of a acidic residue in place of the primed residue. Thus,
the serine-phosphorylation inhibitory mechanism does not nec-
essarily regulate the phosphorylation of non-primed substrates
Fig. 1. Serine9-phosphorylation of GSK3β inhibits its phosphorylation of primed substrates. (A) Representation of GSK3β based on a recently reported crystal structure (Stamos et al.,
2014) showing the adjacent kinase domain and primed-substrate binding domain (based on PDB ID: 4nm0). (B) Phosphorylated serine-9 in the N-terminal tail of GSK3β binds the
primed substrate binding domain (based on PDB ID: 4nm3). (C) Primed substratesﬁrst associatewith the primed substrate binding domain of GSK3β, which places a Ser/Thr four residues
N-terminal to the primed phosphorylated Ser/Thr adjacent to the kinase domain of GSK3β to facilitate substrate phosphorylation. (D) Phosphorylated serine-9 in the N-terminal tail of
GSK3β inhibits the association of primed substrates with the primed substrate binding domain of GSK3β.
116 E. Beurel et al. / Pharmacology & Therapeutics 148 (2015) 114–131
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phosphorylation by GSK-3 is the pre-phosphorylated sequence, S/T-X-X-X-S/T(P), where GSK-
3 phosphorylates a serine/threonine four residues N-terminal to a pre-phosphorylated 
serine/threonine. However, the three-dimensional structure of the substrate also influences its 
interactions with GSK-3. The priming phosphorylation allows the substrate to bind the primed-
substrate binding domain, placing the target serine/threonine adjacent to the kinase domain of 
GSK-3 to facilitate its phosphorylation (Figure 3). In some cases, non-primed substrates may 
contain an acidic residue four amino acids C-terminal from the GSK-3 target site in place of the 
primed phosphorylated residue, such that the acidic residue can interact with the primed substrate 
binding site, but this is not always the case.  
The frequent requirement for a primed substrate is central to two mechanisms that regulate GSK-
3's actions: inhibitory serine phosphorylation of GSK-3, and control of substrate availability. 
Phosphorylation of serine-21 in GSK-3α or of serine-9 in GSK-3β causes the N-terminal tail of 
GSK-3 to act as a pre-phosphorylated substrate, or pseudosubstrate. This phosphorylated serine 
tail self-associates in the primed-substrate binding pocket, hindering the binding of primed 
substrates, and thus diminishing primed-substrate phosphorylation by GSK-3 (Figure 3). Multiple 
signalling pathways feed into this site to increase the serine phosphorylation of GSK-3, which 
can be mediated by Akt, protein kinase A (PKA), protein kinase C, p70 S6 kinase, and other 
kinases. Thus, many signalling pathways that activate these kinases can inhibit GSK-3 by 
phosphorylating the inhibitory serines on GSK-3. An intriguing exception is the recent discovery 
that GSK-3 phosphorylates AMP-activated kinase (AMPK) to inhibit its activity [73]. 
Remarkably, Akt, which usually inhibits GSK-3 by serine-9/21 phosphorylation, promotes 
AMPK phosphorylation by GSK-3, showing that in some circumstances Akt and GSK-3 
cooperatively modulate signalling pathways.  
In general, measuring the serine-9/21 phosphorylation of GSK-3 provides a valuable assessment 
of conditions that regulate the activity of GSK-3 via this mechanism, but it is useful to consider 
four caveats to this conclusion.  
1. Not all substrates of GSK-3 are primed, so these non-primed substrates may not require 
binding to the primed substrate-binding domain to be phosphorylated by GSK-3. Thus, the 
serine-phosphorylation inhibitory mechanism does not necessarily regulate the 
phosphorylation of non-primed substrates by GSK-3.  
2. The activity of GSK-3 in certain protein complexes is not affected by serine-phosphorylation 
of GSK-3. This has been most well-established, and most often misinterpreted, for Wnt 
signalling, which is impervious to the serine-phosphorylation status of GSK-3 bound to Axin,  
3. The serine-phosphorylation status of GSK-3 is probably most often undergoing oscillations, 
thus influencing the basal level of GSK-3 phosphorylation and responsiveness to 
experimental manipulations.   
4. The serine-phosphorylation inhibitory mechanism does not cause absolute inhibition of GSK-
3 activity. In contrast, the phospho-Ser9/21 domain is inhibitory by a mechanism that is 
competitive with primed substrates. As the primed substrate concentration increases it 
displaces phospho-Ser9/21 and once again can be phosphorylated by GSK-3. Thus, the 
 20 
mechanism allows an accumulation of the primed substrate that reaches a new steady-state 
level at which it re-emerges as a substrate of GSK-3.   
Taken altogether, there are many intricacies associated with the serine-phosphorylation 
mechanism of regulating GSK-3, which provide important clues about the regulation of 
signalling systems [71].  
Phosphorylation of ser21-GSK-3α and ser9-GSK-3β can be mediated by a large number of 
different kinases. This allows multiple signalling pathways to impinge on GSK-3, and for GSK-3 
to act as an integrator of signals. It seems likely that the formation of protein complexes has an 
important role in allowing multiple signals and their particular kinases to regulate GSK-3. It is 
also intriguing to note that these are not one-way interactions, but there are clearly bi-directional 
interactions between GSK-3 and kinases that phosphorylate GSK-3, which are likely driven by 
specific signalling pathways in a cell type-specific manner, and there are mechanisms by which 
active GSK-3 can perpetuate its own activity. This bi-directionality has been studied, for 
instance, with the Akt–GSK-3 interaction, in which Akt not only inhibits GSK-3 but GSK-3 can 
also regulate Akt.  
GSK-3 is also phosphorylated at other sites besides serine9/21, but their regulatory outcomes 
remain unclear. Phosphorylation on Tyr216-GSK-3β and Tyr279-GSK-3α, for example, is 
required for maximal activity [72]. During translation, GSK-3 phosphorylates itself on these 
residues so that an active kinase is immediately synthesized. This is another fascinating 
characteristic of GSK-3, during synthesis it can be a tyrosine kinase, but mature GSK-3 is a 
serine/threonine kinase [71].  
Investigators have long thought that GSK-3 must be regulated by additional post-translational 
mechanisms because it seemed that more control is necessary for it to distinguish among 
numerous substrates and to be uniquely regulated by specific signalling pathways. Such 
modifications are finally beginning to be identified. GSK-3 has been reported to be cleaved to 
activated fragments by calpain and by matrix metalloproteinase-2 [74], which may affect its 
selection of substrates to phosphorylate. A regulatory effect of acetylation on GSK-3 activity was 
recently reported. Furthermore, GSK-3β was recently found to be inhibited by mono-ADP-
ribosylation and to be regulated by citrullination [71].  
1.2.3 Substrate pre-phosphorylation and availability  
As previously explained, GSK-3 need for substrate pre-phosphorilation requires temporal and 
spatial coincidence of two signals: induction of the priming substrate phosphorylation and GSK-3 
activation. This means that GSK-3 does not recognize the substrate unless another signalling 
pathway is activated that primes the substrate: signals must be generated to activate a kinase to 
pre-phosphorylate the substrate, GSK-3 must be co-localized with the primed substrate, and the 
timing of signals that activate GSK-3 all must be coordinated to determine if and when GSK-3 
phosphorylates the substrate. This prevents spurious actions of GSK-3 and temporally limits the 
lifetime of primed substrates.  
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For example, the transcription factor cyclic AMP response element binding protein (CREB) is 
not recognized by GSK-3 unless a CREB-activating pathway is turned on that induces 
phosphorylation of CREB on serine-133, which activates CREB. This creates a primed 
phosphorylation site for GSK-3, and in this way intracellular signalling pathways direct GSK-3 to 
its target. However, since GSK-3 is constitutively partially serine-phosphorylated, and thus 
partially inhibited from recognizing primed substrates, another signal coinciding in time and 
intracellular location is required to reduce serine-phosphorylation of GSK-3 to allow it to 
recognize phosphoserine133-CREB. In other words, for nuclear CREB, a signal must cause 
serine-dephosphorylation of GSK-3 in the nucleus at a time when CREB is phosphorylated on 
serine-133. Since phosphorylation of CREB on serine-129 by GSK-3 inactivates CREB, this is 
likely to be the mechanism ensuring that the activation of CREB is transient, an outcome that 
may be employed in transient learning events that require active CREB for a short time. Thus, this 
provides an exquisite mechanism for cycling the actions of GSK-3 substrates.  
1.2.4 Other regulatory Mechanisms  
Subcellular localization  
GSK-3 has traditionally been considered to be largely a cytosolic protein. However, it is also 
present within the mitochondria and nucleus, as well as other subcellular compartments, where its 
levels and/or activation state can be regulated by localized signalling activities. Little is known 
about mechanisms regulating the mitochondrial level and activity of GSK-3, or the mitochondrial 
substrates of GSK-3. In contrast, many nuclear effects of GSK-3 have been identified, 
particularly those involving the regulation of gene expression. GSK-3 enters the nucleus via an 
intrinsic nuclear localization sequence in GSK-3β, and the nuclear levels of GSK-3β rapidly 
increase in response to some apoptotic stimuli. Conversely, the GSK-3-binding protein Frat 
promotes nuclear export of GSK-3. The distinct N-terminal region of GSK-3α causes nuclear 
exclusion that can be counter-activated by calcium signalling [71]  
Actions of GSK-3 affecting nuclear functions, specifically gene expression, include indirect 
effects via its regulation of many transcription factors, and more direct effects resulting from the 
regulation of recently identified epigenetic mechanisms. Among the many transcription factors 
regulated by GSK-3 are Fos/Jun AP-1, CREB, heat shock factor 1, nuclear factor of activated T 
cells (NFAT), myc, C/EBP, NF-κB, p53, signal transducer and activator of transcription-3 
(STAT3), as well as many others. More recently, evidence has begun to reveal significant 
modulatory effects of GSK-3 on proteins involved in epigenetics. Epigenetic regulation by GSK-
3 has been especially well-characterized in the regulation of expression of a subset of NF-κB- 
regulated genes [75]. Thus, by regulating numerous transcription factors and proteins involved 
in epigenetic regulation, GSK-3 has widespread modulatory effects on gene expression [71]. 
Besides these classical nuclear and mitochondrial compartments, GSK-3 is also 
compartmentalized in other subcellular structures and in protein complexes. The localization of 
GSK-3 obviously is important in regulating its actions, but much remains to be learned about 
mechanisms regulating GSK-3 trafficking within cells and the functional consequences.  
 22 
Association in protein complexes  
A major mechanism that has evolved for targeting GSK-3 towards specific substrates is by its 
incorporation into protein complexes that recruit substrates for GSK-3 to phosphorylate. These 
include both preassembled complexes and signal-induced complexes. The classical example of a 
GSK-3-containing preassembled complex is the β-catenin destruction complex in the Wnt 
signalling pathway (Figure 4). In this complex, the scaffold protein Axin, with the assistance of 
the associated protein APC (Adenomatous Polyposis Coli), brings β-catenin into close proximity 
to GSK-3. GSK-3 phosphorylates β-catenin on residues 41, 37, and 33 after priming 
phosphorylation by casein kinase 1, which targets β-catenin to the proteasomal degradation 
machinery. Wnt ligands induce disruption of the complex, which prevents GSK-3 from 
phosphorylating β-catenin, allowing the accumulation and nuclear import of β-catenin. Several 
Axin-binding proteins have been identified that modulate the phosphorylation of β-catenin in the 
Axin–GSK-3 complex, suggesting that much remains to be learned about how signalling 
pathways are integrated at this locus. It is interesting to note that: 
1. As reviewed by Woodgett and colleagues [76], the activity of GSK-3 coupled to Axin is not 
controlled by the GSK-3 serine- phosphorylation mechanism. This independence of 
regulation by GSK-3 serine-phosphorylation may be due to structural constraints that make 
Axin-bound GSK-3 inaccessible to kinases that would otherwise phosphorylate the inhibitory 
serine, or it may be due to the proximity of its primed substrate β-catenin. Taken together 
with the fact that only a very small portion of cellular GSK-3 is bound to Axin, it is evident 
that most phosphoserine-GSK-3 measured in cells is not the GSK-3 that is associated with 
Axin. Thus, it is important to be wary of the often-stated conclusion after an experimental 
treatment that there is a direct relationship between increases in the serine-phosphorylation of 
GSK-3 and increases in the level of β-catenin; these outcomes can occur in parallel but 
increased serine-phosphorylation of GSK-3 does not inhibit GSK-3 in the β-catenin 
destruction complex. This mechanism of insulating Wnt signalling from other pathways that 
regulate serine-phosphorylation of GSK-3 is critical to avoid disastrous activation of Wnt 
signalling by insulin and by every other signal that increases serine-phosphorylated GSK-3.  
2. In many cells, if not all, only a small portion of β-catenin is associated with the Axin 
destruction complex, while much of the β-catenin is intead associated in other protein 
complexes at the plasma membrane. Therefore, it is more informative to measure changes in 
nuclear β-catenin rather than total cellular levels to assess the activity of the Axin-linked β-
catenin destruction complex 
3. β-Catenin is not the only GSK-3 substrate that binds to Axin. Axin also brings other 
substrates into close proximity for phosphorylation by Axin-bound GSK-3, such as Smad3. 
Largely unaddressed are the regulatory consequences of the existence of multiple Axin-bound 
GSK-3 substrates in terms of regulation by serine-phosphorylation or competition between β-
catenin and other GSK-3 substrates for the limited amount of Axin. However, there must be 
some important regulatory interactions between different signalling pathways that utilize the 
Axin–GSK-3-substrate route. For example, cooperative actions of Axin and p53, and several 
p53-regulating proteins, have been demonstrated to regulate both p53 and β-catenin actions 
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and may contribute to the promotion of p53 actions by GSK-3. 
4. The Axin–β-catenin destruction complex has a variety of interactions with Axin-independent 
actions of GSK-3.  
 
Figure 4. The Axin–β-catenin destruction complex (simplified scheme): the pre-assembled complex of Axin, 
Adenomatous Polyposis Coli (APC), casein kinase 1 (CK1), GSK-3β, and β-catenin allows GSK-3 to phosphorylate 
β-catenin sequentially on residues 41, 37, and 33. Phosphorylation leads to the release of β-catenin from the complex 
and targets it for proteasomal degradation. Activation of Wnt signalling disrupts the complex (not shown), blocking 
phosphorylation of β-catenin by GSK-3, resulting in β-catenin stabilization. From [71]. 
.  
In addition to Axin, a growing number of GSK-3-binding proteins, have been identified that 
appear to direct GSK-3 phosphorylation for specific functions, including cell structure and 
adhesion reflecting the importance of protein complexes in allowing signals to regulate the action 
of GSK-3 in a substrate-selective manner. The actions of GSK-3 in protein complexes also 
extend to receptors and receptor-coupled signal transduction systems. It is not known which of 
these protein binding interactions, like Axin, also insulate the activity of GSK-3 from being 
regulated by serine- phosphorylation [71].  
GSK-3 interactions with   receptors and receptor-coupled signal transduction events  
It is now evident that GSK-3 is intimately involved in numerous receptor-coupled signalling 
mechanisms, not only the commonly recognized signalling induced by insulin and Wnt. These 
interactions include regulation of receptor-coupled signal transduction proteins, direct 
interactions with receptors, and regulation of receptor trafficking. G-protein coupled receptors 
(e.g. Dopaminergic D2 receptor, which induces the association of β-arrestin, Akt, GSK-3, and 
protein phosphatase 2A), hormone receptors (e.g. Estrogen Receptor α and β, glucocorticoid 
receptor, androgen and progesterone) and ionotropic neurotransmitter receptors have been shown 
to involve GSK-3 downstream of their activation. These accumulating findings indicate that 
many receptor-mediated signals are regulated by GSK-3, with undoubtedly many more to be 
identified in the near future.  
Kaidanovich-Beilin & Woodgett, 2011), the activity of GSK3
coupled to Axin is not controlled by the GSK3 serine-
phosphorylation mechanism. This independence of regulation by
GSK3 serine-phosphorylationmay be due to structural constraints
that make Axin-bound GSK3 inaccessible to kinases that would
otherwise phosphorylate the inhibitory serine, or it may be due
to thepr ximity of its primed substrateβ-catenin, althoughdetails
of the three-dimensional structure of the complex remain unclear.
Taken along with the fact that only a very small portion of cellular
GSK3 is bound to Axin (Voskas et al., 2010; Kaidanovich-Beilin &
Woodgett, 2011), it is evident that most phosphoserine-GSK3
measured in cells is not the GSK3 that is associated with Axin.
Thus, it is important to be wary of the often-stated conclusion
after an experimental treatment that there is a direct relationship
between i creases in the serine-phosphorylation of GSK3 and
increases in the level of β-catenin; these outcomes can occur in
parallel but increased serine-phosphorylation of GSK3 does not
inhibit GSK3 in the β-catenin destruction complex. This mecha-
nismof insulatingWnt signaling from signaling induced by insulin
and other pathways that regulate serine-phosphorylation of GSK3
is not only ingenious as only nature can be, but it is obviously crit-
ical to avoid disastrous activation of Wnt signaling by insulin and
by every other signal that increases serine-phosphorylated GSK3.
Thus, numerous reports that certain conditions increase the
serine-phosphorylation of GSK3 and elevate β-catenin levels
should not be interpreted as a cause-and-effect relationship be-
tween these two events.
(ii) In many cells, if not all, only a small portion of β-catenin is associ-
ated with the Axin destruction complex, with much of the
β-catenin instead being associated in other protein complexes at
the plasma membrane. Therefore, changes in total cellular levels
of β-catenin often do not reﬂect changes in the activity of the
Axin-linked β-catenin destruction complex. Rather, it is more in-
formative tomeasure changes innuclearβ-catenin,which increase
after the Axin–β-catenin destruction complex is inactivated.
(iii) β-Catenin is not the onlyGSK3 substrate that binds toAxin (Fig. 3).
Although Wnt signaling is most often the subject of studies of
Axin–GSK3-substrate interactions, Axin also brings other sub-
strates into close proximity for phosphorylation by Axin-bound
GSK3 (N.G. Kim et al., 2009), such as Smad3 (Guo et al., 2008), tu-
berous sclerosis complex-1 (TSC1)/hamartin and TSC2/tuberin
(Mak et al., 2003, 2005; Rosner et al., 2008). Largely unaddressed
are the regulatory consequences of the existence of multiple
Axin-bound GSK3 substrates, e.g., is the phosphorylation by
GSK3of other Axin-bound substrates also impervious to regulation
of GSK3 by serine-phosphorylation? Is there competition between
β-catenin and other GSK3 substrates for the limited amount of
Axin? Less than 10% of cellular GSK3 has been estimated to be as-
sociated with Axin (Voskas et al., 2010; Kaidanovich-Beilin &
Woodgett, 2011), indicating that the level of Axin is limiting, not
the GSK3 level, for substrates requiring binding to Axin to be phos-
phorylated by GSK3. Thus, there are likely some important regula-
tory interactions between different signaling pathways that utilize
the Axin–GSK3-substrate route, e.g., how is priority determined
between Axin-bound GSK3 substrates, and does this provide an
integrative mechanism, or competition, between signaling path-
ways? For example, cooperative actions of Axin and p53, and
several p53-regulating proteins such as Tip60 (Fig. 3), have been
demonstrated to regulate both p53 and β-catenin actions (Levina
GSK3β
Axin
β-Cat
APC
CKIβ-Cat
P
P
P
PP P
P
P
PP
PP
Fig. 2. The Axin–β-catenin destruction complex. A simpliﬁed scheme is shown of the pre-
assembled complex of Axin, Adenomatous Polyposis Coli (APC), casein kinase 1 (CK1),
GSK3β, andβ-catenin,which allowsGSK3 to phosphorylateβ-catenin sequentially on res-
idues 41, 37, and 33. Phosphorylation leads to the release of β-catenin from the complex
and targets it for proteasomal degradation. Activation of Wnt signaling disrupts the com-
plex (not shown), blocking phosphorylation of β-catenin by GSK3, resulting i β-c tenin
stabilization (MacDonald et al., 2009; Valvezan & Klein, 2012; Willert & Nusse, 2012).
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Fig. 3.Axin associateswith several GSK3 substrates. Axin binds to several GSK3 substrates to facilitate their phosphorylation, such as (A) Smad3, (B) tuberous sclerosis complex-1 (TSC1),
and (C) TSC2. (D) The GSK3 substrate Tip60 also binds to Axin, which may facilitate its phosphorylation by GSK3 that activates Tip60. Tip60-mediated regulation of p53 is also
modulated by Axin-bound HIPK2 (homeodomain-interacting protein kinase 2), raising the hypothetical possibility depicted here of a multi-protein complex that regulates both Tip60
and p53. (A–D) It is not known if these GSK3 substrates compete with β-catenin to bind the same domain of Axin, or if distinct binding sites on Axin exist for each substrate. Binding
of all substrates to the same region of Axin is depicted here because this places the substrates adjacent to GSK3 for phosphorylation.
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Other mechanisms regulating the actions of glycogen synthase kinase-3  
GSK-3 seldom appears to be regulated by changes in expression, as only a few conditions have 
been reported in which the expression or levels of GSK-3 are markedly altered. However, large 
changes in GSK-3 levels can occur; for example there is a large, ~10-fold increase in GSK-3β in 
the Th17 subtype of T cells, relative to other T cells [77].  
Single nucleotide polymorphisms (SNPs)  have been identified in the GSK-3β gene that may be 
linked to disease susceptibility or responses to therapeutic drugs. Alternative splicing can give 
rise to forms of GSK-3β with altered functions. 
Altogether, in contrast to the common notion that GSK-3 is only regulated by serine-
phosphorylation and by binding to Axin, there is a plethora of mechanisms that guide the actions 
of GSK-3. These mechanisms apparently provide the underpinnings for GSK-3 to select among 
its many substrates in response to each signalling pathway that impinges upon GSK-3.  
1.2.5 Differential actions and regulation of GSK-3α and GSK-3β  
An emerging topic is the identification of differential regulation and actions of GSK-3α and 
GSK-3β. The catalytic domains of GSK-3α and GSK-3β are nearly identical, but their C-
terminal sequences diverge and GSK-3α contains a large glycine-rich N-terminal region that is 
absent in GSK-3β [76]. Surprisingly, little is known about mechanisms that differentially regulate 
their expressions, except for the novel discovery that the GSK-3α gene is absent in birds. 
Reported expression differences include the selective up-regulation of GSK-3β expression in the 
Th17 subtype of T cells, which are pathogenic in autoimmune diseases [77], and differences in 
the expression of GSK-3α and GSK-3β in mouse brain regions during development and in the 
suprachiasmatic nucleus during the circadian rhythm. Studies of mechanisms that differentially 
regulate the expression of GSK-3α and GSK-3β are needed to identify signals that control the 
expression of each isoform.  
For many years GSK-3α and GSK-3β were often considered as identical twins, in part because 
all known GSK-3 inhibitors inhibit both isoforms so it was difficult to identify differential effects 
of the two isoforms. Unfortunately, many studies have attributed the outcomes of treatments with 
GSK-3 inhibitors specifically to GSK-3β, leading to incorrect conclusions that GSK-3β 
selectively mediates the processes under investigation. There is also a widely held misconception 
that certain commercially available GSK-3 inhibitors are specific for one isoform, but there is not 
a commercially available GSK-3 inhibitor that is selective for either isoform, although there is 
some progress in the development of GSK-3 isoform-selective inhibitors [78].  Recently, 
different actions of the GSK-3 isoforms have begun to be identified, primarily due to the advent 
of knockout and knockdown methods. Identifying individual actions of GSK-3α and GSK-3β 
was particularly stimulated by the finding that GSK-3β knockout mice are embryonically lethal, 
whereas GSK-3α knockout mice are viable, which provided an important demonstration that the 
two isoforms are not interchangeable. Studies in GSK-3α knockout mice, GSK-3β+/− 
heterozygote knockout mice, and with partial suppression of GSK-3β expression in mouse brain, 
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have demonstrated functions regulated by each isoform. However, in most cases this approach 
does not prove isoform-specific actions, as it may be unclear if the outcomes of isoform reduction 
are due to lower total levels of GSK-3, or to isoform-specific effects, unless outcomes of 
individually knocking down GSK-3α and GSK-3β are compared.  
Although many substrates appear to be phosphorylated by both GSK-3 isoforms, there is a 
growing recognition that certain substrates are preferentially linked to one isoform and that the 
two isoforms differ in certain regulatory functions. As might be expected, since GSK-3α and 
GSK-3β have differences in their functional effects, there is also evidence of differences in 
signalling mechanisms that regulate the two isoforms. Since further identification of mechanisms 
that differentially regulate GSK-3α and GSK-3β may lead the way towards the development of 
interventions that can predominantly affect one isoform more than the other, this topic is likely to 
receive much attention in the near future [71]. 
 
 
1.2.6 Targeting glycogen synthase kinase-3 therapeutically  
GSK-3 takes part into many signalling pathways associated with pathogenesis of different 
diseases, so it is not surprising that it is under investigation as a therapeutic target in multiple 
disorders. On the other hand, the great number of substrates that are phosphorylated by GSK-3 
raises the question of whether this limits its feasibility as a therapeutic target, due to the potential 
disruption of many cellular processes. Based on over 60 years of safe and successful treatment of 
bipolar disorder with lithium, it is evident that a GSK-3 inhibitor can be tolerated and effective 
for many years, regardless of whether or not lithium's inhibition of GSK-3 contributes to its mood 
stabilization effects, which is still a matter of debate. Another important consideration is the 
extent to which GSK-3 should be inhibited therapeutically. As discussed previously, therapeutic 
levels of lithium only partially inhibit GSK-3, and this may be optimal for dampening GSK-3's 
self-activating mechanisms in disease processes while allowing GSK-3 to fulfil, unhindered, its 
many other cellular actions. In addition to the potential benefit of only partial inhibition of GSK-
3, developing disease-selective inhibitors of GSK-3 should be possible based on the many 
previously listed mechanisms that regulate GSK-3. For example, it has already been developed an 
effective GSK-3 inhibitor peptide derived from the sequence of the GSK-3 primed substrate 
CREB, and a peptide inhibitor of GSK-3 that is primed by Akt-dependent phosphorylation was 
shown to be effective after insulin treatment. As more is learned about the mechanistic 
involvement of GSK-3 in individual diseases, it may be possible to develop inhibitors that 
predominantly block the actions of GSK-3 that are involved in pathological mechanisms. Thus, 
one goal for future development of therapeutic GSK-3 inhibitors will be to target specific cells or 
signalling pathways. Even as we await these developments, GSK-3 is already being considered as 
a therapeutic target in multiple conditions, as discussed below. 
Psychiatric diseases  
Psychiatric diseases are likely to be one of the major classes that are amenable to GSK-3 inhibitor 
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therapeutics. Patients with bipolar disorder, are already being effectively treated with lithium and 
there is no doubt that lithium is a GSK-3 inhibitor. Although the therapeutic mechanism of action 
of lithium remains to be definitively determined, substantial evidence indicates that inhibition of 
GSK-3 is an important component of lithium's mood stabilizing capacity. Lithium directly binds 
and inhibits GSK-3 by competing for a Mg2+ binding site. Besides directly inhibiting GSK-3, 
lithium administration at therapeutically relevant levels (i.e., near 1 mM lithium in the serum) 
also increases the inhibitory serine-phosphorylation of GSK-3 in rodent brain in vivo and in 
many other cell types, which can result from those amplification mechanisms previously 
discussed. Peripheral blood mononuclear cells from patients treated with lithium display 
increased serine-phosphorylated GSK-3, confirming that therapeutic levels of lithium inhibit 
GSK-3 and increase its inhibitory serine-phosphorylation in humans [71].  
It is worthy to underline some of the implications of the increased serine-phosphorylation of 
GSK-3 induced by lithium. First, this induction only occurs with pools of GSK-3 that are subject 
to GSK-3's self-regulation via modulating phosphatases or other mechanisms previously 
discussed. Thus, the serine-phosphorylation of all cellular GSK-3 may not be equally affected by 
lithium. Second, this serine-phosphorylation of GSK-3 mechanism of action leaves untouched 
the activity of GSK-3 in the Wnt signalling pathway, and perhaps in other protein complexes. 
However, the direct inhibitory effect of lithium on GSK-3 is often sufficient to impede β-catenin 
degradation. Third, serine-phosphorylation of GSK-3 only inhibits its phosphorylation of primed 
substrates. Furthermore, accumulated primed substrates eventually can out-compete the 
phosphoserine of GSK-3 for binding to the primed substrate-binding pocket. Thus, the lithium-
induced increase of serine-phosphorylated GSK-3 does not completely block its phosphorylation 
of primed substrates, but instead leads to a new increased steady state level of the primed 
substrate. It can be speculated that this may be crucial for allowing lithium to be therapeutic 
without completely blocking all of GSK-3's actions.  
In addition to the substantial evidence that GSK-3 inhibition is therapeutic for bipolar disorder, 
there is evidence that GSK-3 inhibitors may contribute to therapies for depression, anxiety (, and 
schizophrenia.  
Neurological diseases  
There is abundant evidence that inhibition of GSK-3 is likely to be therapeutic for a number of 
neurological disorders. The evidence is particularly strong for Alzheimer's disease [79], where, 
GSK-3 has been demonstrated to promote every major pathological process, including amyloid β 
peptide production and tau phosphorylation, which lead to the two hallmark pathologies of 
Alzheimer's disease, amyloid plaques and neurofibrillary tangles, respectively. Much evidence 
also demonstrates that GSK-3 inhibitors improve many cognitive functions in rodent models of 
Alzheimer's disease. Encouraging findings for targeting GSK-3 have been identified in 
examinations of dementia development in bipolar patients that have been treated with lithium for 
long periods of time, as these patients often have a lower prevalence of dementia than the general 
population. Clinical trials of lithium in Alzheimer's disease have demonstrated some beneficial 
effects [80], although not in all studies.  
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Studies in rodent models have also demonstrated evidence of therapeutic effects of GSK-3 
inhibitors in several other neurological disorders, e.g. Fragile X syndrome. There is also 
exceptionally strong evidence from mouse models that GSK-3 inhibitors are able to ameliorate 
the autoimmune disease multiple sclerosis, whose onset and progression are thought to be due to 
a combination of the effects of inflammation and pathogenic T cells, particularly Th17. Studies 
also have underlined the potential therapeutic benefits of GSK-3 inhibitors in several models of 
Parkinson's disease, Huntington's disease, stroke, traumatic brain injury and spinocerebellar 
ataxia type 1. 
Most of the above mentioned diseases involve inflammation and neurodegeneration, and GSK-3 
inhibitors are strong anti-inflammatory agents and neuroprotectants, reducing apoptosis after a 
wide range of insults. In addition to apoptosis, GSK-3 inhibitors also provide neuroprotection by 
other mechanisms, in particular multiple regulatory influences on dendrite and axon growth and 
repair. In some conditions, regulation of several components of the circadian rhythm by GSK-3 
may also make a significant contribution. Thus, there are multiple mechanisms by which 
inhibition of GSK-3 may contribute to therapies of neurological and psychiatric disorders.  
Inflammatory diseases  
Diseases involving inflammation in the periphery have also been shown to benefit from the anti-
inflammatory effects of GSK-3 inhibitors [81]. Remarkably, administration of GSK-3 inhibitors 
was sufficient to afford mice protection (survival) from an otherwise lethal dose of the 
inflammatory stimulant lipopolysaccharide used to model sepsis [82]. Administration of GSK-3 
inhibitors also reduced inflammation and pathology in rodent models of asthma, arthritis, colitis, 
and peritonitis. Thus, GSK-3 inhibitors provide an effective intervention for all inflammatory 
diseases in which they have been tested in rodent models.  
The strong pro-inflammatory action of GSK-3 in multiple peripheral and CNS diseases raises the 
question of why evolutionary mechanisms did not provide the means to more adequately down-
regulate the activity of GSK-3 in inflammatory conditions. It could be hypothesized that a 
significant survival benefit is achieved by GSK-3 promoting responses to infection and stress, 
both of which activate inflammatory responses. Thus, survival may have benefited from GSK-3 
promoting both innate and adaptive immune responses, increasing the production of multiple 
inflammatory cytokines and promoting the production of Th1 and Th17 inflammatory T cells, 
which should increase resistance to injury and infection. However, these same innate and 
adaptive immune responses can exacerbate chronic conditions that have become more prevalent 
in modern societies, such as neurodegenerative diseases, mood disorders, asthma, arthritis, and 
diabetes. Therefore, GSK-3 inhibitors provide feasible means to counteract excessive 
inflammation that is involved in a diverse number of chronic conditions.  
Cancer  
There is much interest in GSK-3 as a potential therapeutic target in many types of cancer. 
However, this application is complicated by findings that GSK-3 can act as a tumor suppressor or 
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it can promote cell proliferation in different types of cancer. The tumor suppressor action is 
exemplified by GSK-3-mediated phosphorylation of β-catenin and its subsequent degradation, a 
transcriptional co-activator that often promotes cellular proliferation. There is evidence that 
GSK-3 acts as a tumor suppressor in some skin and breast cancers. On the other hand, the tumor 
promoting actions of GSK-3 are indicated by the elevated levels of GSK-3 present in certain 
types of tumors and/or by the anti-proliferative effects of GSK-3 inhibitors, such as in colon and 
pancreatic cancers, in Non Small Cell Lung Cancer [83] and in mixed lineage leukemia. 
These differences in the actions of GSK-3 in various types of cancer may have obstructed the 
development of GSK-3 inhibitors for cancer. Examination of the mechanisms underlying the 
opposite actions of GSK-3 in different types of cancer may provide opportunities to better 
understand the mechanistic cellular changes and to identify those that may safely benefit from 
GSK-3 inhibitor administration. In fact the type of apoptosis (GSK-3 has opposite actions on the 
intrinsic and extrinsic apoptotic signalling pathways), the role of β-catenin, and the actions of 
NF-κB are likely important in the actions of GSK-3 and its inhibitors in specific cancers, making 
it difficult to harness potential therapeutic interventions.  
Other conditions  
In addition to the diseases discussed here, potential therapeutic applications of GSK-3 inhibitors 
have been explored in other prevalent conditions, including cardiovascular diseases [84], AIDS, 
bone disorders, and diabetes.  
 
1.2.7 GSK-3 inhibitors 
 
Apart from Lithium, several GSK-3 inhibitors have been recently developed and more than 30 
are currently available, most of which acting with a ATP competitor mechanism[85]. Among 
ATP competitor GSK-3 inhibitors it is worthy to mention Aloisines, Hymenialdisines, Indirubins, 
and Maleimides, among not ATP competitor the Tiadiozolidinoni (TDZD), including Tideglusib 
which is currently involved in phase II-III trials. As previously explained, there is not a 
commercially available inhibitor that is selective for either GSK-3 isoform, although there is 
some progress in the development of GSK-3 isoform-selective inhibitors [78]. SB216763 and 
SB415286 are two structural distinct maleimides (Figure 1.12), able to travel across the plasma 
membrane, acting as ATP competitors selectively on GSK-3α and GSK-3β. These two 
compounds have been shown to drastically reduce the GSK-3 activity; indeed they were able to 
induce all the answers induced by GSK-3 inhibition and resulted useful drugs in the study the 
role of GSK-3 in different signal pathways [86].  
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Figure 5. Structure of GSK-3 inhibitors SB216763 and SB415286 
 
 
1.2.8 GSK-3 in the context of fibrosis 
 
The role of GSK-3 in the context of fibrosis has been studied in different tissues, including liver, 
heart  and lung. Only few data are available on the role of GSK-3 in the context of pulmonary 
fibrosis 
 
It is believed that distinct intracellular pools of GSK-3 can simultaneously regulate divergent 
signalling pathways within the same cell, and the large number of putative substrates suggest that 
GSK-3 act as a key regulator of cellular processes in fibroblasts (Ding et al., 2000; Götschel et 
al., 2008). However, the role of GSK-3 signalling in human lung fibroblasts function is still 
largely unknown. Previous studies have tried to assess the contribution of GSK-3 signalling to 
myofibroblast differentiation of human primary lung fibroblasts. It has been reported a critical 
involvement of the GSK-3 signalling in the TGF-β1-induced myofibroblast differentiation, 
pointing either on his negative role by inhibiting β-catenin nuclear translocation or on its positive 
role by regulating CREB-dependent signalling. Thus, GSK-3 inhibition has been suggested either 
as a pro-fibrotic strengthening of TGFβ1-dependent differentiation to myofibrobasts, due to β-
catenin accumulation [87], or as a possible anti-fibrotic strategy, due to the consequent phospho-
CREB-mediated antagonism of TGFβ/SMAD signalling [88] (Figure 6).  
 
In epithelial alveolar type 2 cells and in other epithelial cell types GSK-3 has been shown to 
negatively regulate epithelial to mesenchymal transition (EMT) [89]. 
 
We previously demonstrated the in vivo anti-inflammatory and anti-fibrotic properties of the 
specific inhibitor of the kinase GSK-3, SB216763, in a mouse model of BLM-induced lung 
fibrosis [90]. 
 
Therefore it seems that GSK-3 role is context and cell type-dependent and, in the still poorly 
understood pathogenesis of pulmonary fibrosis, more investigation is needed to assess the exact 
role of GSK-3. It is likely that cell to cell interaction and in vivo pro-fibrotic microenvironment 
(including ECM) can significantly influence the consequences of GSK-3 inhibition.  
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Figure 6. Two different GSK-3 roles in myofibroblast differentiation. (a) GSK-3 
pharmacologic inhibition increases availability of β-Catenin, due to its reduced degradation, 
which moves into the nucleus and drive myofibroblast differentiation [87]. (b) Pharmacologic 
inhibition of GSK-3 allows the phosphorilaiton of CREB, which in turn acts as an antagonist of 
the TGF-β/smad signalling [88]. 
 
 
 
1.3 Pulmonary fibrosis mouse model 
 
A universally trusted in vivo or in vitro model of IPF is still lacking. Nonetheless, experimental 
lung fibrosis models are routinely used for the identification of relevant underlying pathogenic  
mechanisms and assessment of drug efficacy. Unfortunately, IPF research is hampered by animal 
models that do not recapitulate all the features of the human disease, and whose ability to predict 
future clinical outcomes has been questioned. From the plethora of pathways/targets that show 
anti-fibrotic potential in these experimental models, few have gone on to show benefit in clinical 
trials [91]. Several different models exist [92], of which lung fibrosis induced by bleomycin 
application is probably the best characterised and most widely utilised, although there is no 
accepted standardised version of this model [93]. A variety of factors will affect the nature of the 
fibrotic response, including the route of administration, the bleomycin preparation, dose, mouse 
strain, age and so on. Prophylactic dosing schedules and nonconditional genetically deficient 
mouse studies often report beneficial effects, but potentially not through a direct antifibrotic 
response, but instead by dampening the early inflammatory reaction to bleomycin [94]. 
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However, the BLM-induced mouse model of pulmonary fibrosis is still considered, by many 
researchers, the gold standard in the field of IPF and evidence deriving from this mouse model 
are still required before moving to phase I clinical trials for possible new IPF-targeted drugs. 
 
 
1.3.1 Bleomycin 
Bleomycin (Figure 7) is a glycopeptide of 1.5 kDa produced by Streptomyces 
verticillus[95]. This molecule has antitumor and antiviral activity and acts mostly by blocking the 
cell cycle in G2 phase. The bleomycin stimulates the lung damage through its ability to interlayer 
the DNA every 5 base pairs, inducing a site specific nick (between G-C and G-T bases) and a 
non-specific nick both in the single and in double helix. Moreover bleomycin is able to inhibit the 
DNA repair enzymes such as DNA ligase. This compound is usually degraded by bleomycin-
hydrolyse enzymes, that are expressed in several tissues, except skin and lung. In the extremities 
this molecule presents a DNA and Fe2+ binding regions. The Fe2+ binding region is necessary 
because acts like co-factor able of damaging the DNA with the consequent cytotoxic effect. 
 
 
 
Figure 7. Chemical structure of bleomycin 
 
This drug is in clinical use for chemotherapy of neoplasms such as squamous cell 
carcinoma of the cervix, oesophagus, skin, lung, neoplasms of testis germ cells, Hodgkin and 
non-Hodgkin lymphomas. Unfortunately, 10% of patients treated with a cumulative dose of 
bleomycin upper than 200U/m2 develops interstitial pneumonia, that progresses to fibrosis. In 
terms of pathogenesis of lung inflammation, it has been demonstrated that the stimulation of 
Toll-like receptor 2 (TLR2) by bleomycin itself induces the activation of monocytes and pro-
inflammatory chemokine release[96]. The ability of innate immune system to recognize and 
replay to exogenous agents is largely attributed to the Toll-like receptors family (TLRs). These 
receptors are mostly expressed on the surface of antigen presenting cells (APC) such as 
monocytes, macrophages and dendritic cells, and are able of discriminating among separate 
molecular patterns associated to microbial elements. The recognition by these receptors of 
products of pathogens stimulates several transduction signalling pathways that regulate the type, 
the scope and the duration of inflammatory response. In this context the inability of host itself to 
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regulate the type or duration of inflammatory response is critical, as in the case of inflammatory 
chronic diseases. The stimulation of TLR2 by bleomycin causes the activation of NF-κB, which 
in turn induces the transcription of genes for pro-inflammatory chemokines such as IL-8, IL-1β e 
TNF-α [96].  
 
1.3.2 BLM-induced mouse model of Pulmonary Fibrosis 
 
The pulmonary dose-dependent toxicity of bleomycin turned out to be useful to create 
experimental models of IPF in animals. Though several studies have highlighted the presence of 
important differences between the acute and the chronic phase in the pulmonary fibrosis of 
animals, the mouse model represents an evaluable tool in order to verify, in vivo, the proteins and 
the molecules involved in the pathogenesis of pulmonary fibrosis. Moreover the possibility to 
manipulate genetically the mice, creating knock out models, is useful to demonstrate the 
involvement of specific genes in pneumonia characterized by fibrosis development. In the mouse 
model of BLM-induced pulmonary fibrosis, the initial event is represented by the damage to 
epithelial lung cells, that stimulates the migration of granulocytes and fibroblasts into the injured 
tissue and the consequent migration of macrophages, lymphocytes and fibroblasts. The 
development of an acute inflammation is finally followed, within 21-28 days, by interstitial 
fibrosis. Only in some cases these mechanisms cause a "respiratory distress syndrome" leading to 
rapid death of animals before the establishment of fibrosis. This mouse model of pulmonary 
fibrosis draws near some key characteristics of human pulmonary fibrosis, including the damage 
to alveolar epithelial cells, recruitment of inflammatory cells, proliferation and activation of 
fibroblasts responsible of extracellular matrix production and deposition in the pulmonary 
parenchyma. The anatomic-pathologic characteristic of lung lesions, in particular, specifically 
recall the characteristic pattern of UIP found in IPF human pulmonary biopsies. Nonetheless 
there are also significant differences between the mouse model and the human IPF. First of all, in 
human beings, disease is diagnosed when fibrosis is already established and the early natural 
history of IPF, its causal factors and pathogenetic mechanism, are not anymore comprehensible. 
Second, the updated pathogenetic hypotheses significantly down-graded the role of inflammation 
in fibrosis establishment, whilst inflammation is definitely the primum movens in BLM-driven 
lung damage. Third, mouse underwent BLM administration, when surviving after the acute phase 
and not dying due to respiratory failure around day +28 experience complete spontaneous 
resolution of fibrotic process. This last point has been partially contradicted by a recent micro-CT 
based study, showing how the fibrotic lesions did not completely resolve, but instead persisted 
for several months following a single insult with bleomycin [94]. Thus, lacking a trustable in 
vitro model of disease and given the impossibility to only consider the information obtained by 
human pulmonary biopsies and to directly test new drugs on human beings, the role of an animal 
model that can reproduce, as faithfully as possible, the characteristics of IPF [97] is still 
irreplaceable. 
 
 
 
 
 33 
1.3.3 GSK-3 in the mouse model of pulmonary fibrosis 
 
We previously demonstrated the anti-inflammatory and anti-fibrotic properties of the specific 
inhibitor of the kinase GSK-3, SB216763, in a mouse model of BLM-induced lung fibrosis. In 
particular, GSK-3 resulted greatly expressed in the sites of inflammation and fibrosis and its 
inhibition reduced the recruitment of T-lymphocytes, the neutrophil activation and the expression 
of the macrophagic cytokines TNF-α and MCP-1, evidencing a key role of this Ser-Thr kinase in 
lung inflammation. Moreover, the late administration of the molecule has been shown to directly 
affect fibrosis, irrespective of the previous inflammatory phase of the process [90]. 
 34 
2.  AIM OF THE PROJECT 
 
In this study, we used the BLM mouse model to investigate the role of the kinase GSK-3 and 
its SB216763-mediated inhibition in modulating the expression and activity of MMP-9 and 
MMP-2 and their inhibitors TIMP-1 and TIMP-2 in the development of BLM-induced fibrosing 
alveolitis. We focused on Brocho-Alveolar Lavage Fluid (BALF) and lung tissue expression of 
MMPs and TIMPs. We also investigate the impact of GSK-3 silencing or knock-out on A549 and 
MEF cell lines, respectively, as models of epithelial alveolar type 2 cells and lung fibroblasts. A 
better understanding of GSK-3 role in pulmonary fibrosis development and, in particular, in 
modulation of ECM remodelling is the first step to assess the suitability of this kinase as potential 
therapeutic target in IPF. 
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3. METHODS 
 
3.1.  Drugs  
 
Betadine: povidone-iodine (PVPI) topical antiseptics (B/BRAUN, Milan, Italy). 
Zoletil: combination of a dissociative anesthetic agent, tiletamine hypochloride, and a 
tranquilizer, zolazepam hypochloride (Virbac.srl, Milano, Italy). This drug is used for injection 
anaesthesia in dogs, cats, wild and zoo animals. It produces dose-dependent sedation to general 
anaesthesia. 
Xilor: xylazine is a muscle relaxant and sedative drug, for veterinary use (bio98 srl, Milano, 
Italy). It is often used in combination with zolazepam in general anaesthesia. 
Bleomycin: glycopeptide antibiotic (Aventis Pharma SpA, Varese, Italy) produced by the 
bacterium Streptomyces verticillus. This drug acts by induction of DNA strand breaks and it is 
used in the treatment of several diseases, such as Hodgkin lymphoma (as a component of the 
ABVD regimen), squamous cell carcinomas, testicular cancer, pleurodesis as well as plantar 
warts.  
SB216763: highly selective GSK-3 inhibitor (Sigma-Aldrich, St. Louis, MO, USA). This 
compound is an arylindolemaleimide that inhibits GSK-3 in an ATP competitive manner [86, 
98]. 
SB203580: MAPK p38 inhibitor (Sigma-Aldrich, St. Louis, MO, USA) 
PD98059: ERK inhibitor (Sigma-Aldrich, St. Louis, MO, USA)  
TNFa: (Sigma-Aldrich, St. Louis, MO, USA) 
 
3.2  Mouse model 
 
Mice 
 
C57BL/6N mice obtained from Charles River, Jackson Laboratories Inc. (Milan, Italy), were 
used for this study. Mice were housed under ethical conditions in a pathogen-free animal facility. 
Mice were used at 12 weeks of age. All procedures were approved by local Animal Care 
Committee of the University of Padova (Padova, Italy). 
 
Experimental protocol 
 
C57BL/6N mice were randomized into four different subgroups as previously described: 
(Gurrieri C. et al., JPET, 2010): one treated with saline and another one treated with saline plus 
SB216763 as control groups, one treated with BLM plus vehicle and the last one treated with 
BLM plus SB216763. Mice were anesthetized with an intraperitoneal administration of a mixture 
of ZOLETIL 100 (40-80 mg/Kg) and XILOR. Trachea was surgically exposed and sterile 
isotonic saline or bleomycin sulfate (3 U/Kg) (Aventis Pharma SpA, Varese, Italy) was instilled 
into the trachea through a 29-gauge needle. SB216763 (20 mg/Kg) (Sigma-Aldrich, St. Louis, 
MO) dissolved in dimethhyl sulfoxide and polyethylene glycol was administered 
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intraperitoneally twice a week. Mice were sacrificed 7 or 28 days after BLM or saline 
administration by CO2 narcosis. The lungs from different animals were processed for 
immunohistochemical and biochemical studies; all lobes underwent histological analysis, 
separately.  At the time of sacrifice, mice underwent broncho-alveolar lavage  (BAL). 
 
Bronchoalveolar Lavage (BAL) and cell count in BAL fluid (BALF) 
 
Trachea was exposed and isolated in the site previously sutured and airspaces were lavaged three 
times with 0.5 ml of sterile saline. BAL was centrifuged and supernatant was stored at -80°C for 
the zymographic analysis. BAL cells were adjusted to the final concentration of 1 x 106 cells/mL 
in phosphate buffer saline and total cell counts were performed by manual counting under light 
microscopy with a standard haemocytometer chamber. Finally, 100 mL of BAL cells were 
smeared on a glass slide and then stained with May-Grünwald Giemsa dyes. Differential counts 
on 200 cells were made using standard morphological criteria.  
 
3.3  Histology 
 
Lung tissues were fixed in formalin, embedded in paraffin and dissectioned in 4-5μm slices. 
Subsequently they were stained with Hematoxylin&Eosin (H&E), to evaluate the degree of 
inflammatory cell infiltration and epithelial alveolar cuboidalization and stained with Masson’s 
trichrome to evaluate the degree of interstitial fibrosis. Then, each section was scanned at 40X 
magnification to identify at least 5 areas (hot spots) with the largest extension of fibrosis 
(Trichrome staining). Each hot spot was then examined at X 200 magnification (0.949 mm²/field) 
and the fibrosis was quantified by using digital quantitative analysis (Image Pro Plus software 
version 4.1, Media Cybernetics, Silver Spring MD). The mean value of the five areas was taken 
as representative of the whole section. 
 
Histochemistry 
  
Lung sections were first washed in 1% H202 PBS and then blocked for 30 minutes in 1% FCC 
and 0,3% Triton X-100 blocking medium. They were then incubated with primary antibodies 
(MMP9, MMP2, TIMP1 and TIMP2, 1:500; Santa Cruz Biotechnology, CA). Sections were 
subsequently washed in PBS and incubated with second stage biotinylated antibodies. After  
diaminobenzidine (DAB) staining and hematoxylin counter-staining, sections were mounted in 
Poly-Mount medium (Polysciences, Warrington, PA). 
 
3.4  Gelatin Zymography 
 
Aliquots of BAL fluid were mixed with 4X non reducing sample buffer (1,25M Tris-HCL pH 
6.8, 10% (w/v) sodium dodecyl sulfate (SDS), 40% (v/v) glycerol, 1% bromophenol blue) (3:1, 
v/v) and electrophoresed on 8% SDS-PAGE containing 1% gelatin (Sigma-Aldrich, St. Louis, 
MO) as MMP-9 and MMP-2 substrate. Following electrophoresis the gels were washed twice 
with 2.5% Triton X-100 and then incubated overnight at 37°C in developing buffer (50mM Tris-
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based, 200mM NaCl, 10mM CaCl2, pH 7.4). The gels were stained with 0.5% (w/v) Comassie 
Brilliant Blue R-250 (Sigma-Aldrich) in 30% methanol and 10% acetic acid and destained in a 
solution of 30% methanol and 10% acetic acid. Gelatinases appear as clear bands against blue 
background. (We used recombinant protein molecular weight markers to estimate the weights of 
the gelatinolytic bands.) Relative enzyme amounts were quantified by measuring the intensity of 
the bands with the pixel-based densitometer program Quantity One®, 1-D Analysis Software 
(Bio-Rad Laboratories, Inc., Hercules CA).  
 
3.5  Western blot analysis 
 
Protein quantitation has been performed using Bradford staining (Sigma-Aldrich) and 
spectroscopic analysis before running in SDS-page electrophoresis. Primary antibodies: GAPDH 
monoclonal (Ambion, USA), MMP-9 policlonal (Millipore, MA, USA), TIMP-1 policlonal 
(Millipore, MA, USA), p38 and phospho-p38 (Tyr180/Tyr182) (Cell Signalling, MA, USA), 
SAP-JNK and SAP-JNK Thr180/Tyr185 (Cell Signalling), ERK and ERK Thr202/Tyr204 (Cell 
Signalling), p65 and phospho-p65 (Ser536) (Cell Signalling), IKBα and phospho-IKBα 
(Ser32/Ser36) (Santa-Cruz) and GSK-3 total (Santa Cruz). Secondary antibodies: rabbit anti-
mouse HRP-conjugated and policlonal goat anti-rabbit GE Healthcare (Buckingamshire, UK)  
 
3.6  Quantitative real-time PCR amplification 
 
Total lung RNA was extracted from mouse lungs using TRIzol reagent (Invitrogen Life 
Technologies, Grand Island, NY) and reversed transcribed into cDNA using Reverse 
Transcription System (PROMEGA, Madison, WI) according to the manufacturer’s instructions. 
Quantitative real-time PCR amplification was performed on an ABI PRISM 7000 sequence 
detection system (Applied Biosystems, Foster City, CA). Reactions were carried out with 
Platinum® SYBR® Green qPCR SuperMix-UDG kit (Invitrogen Life Technologies, Carlsbad, 
CA). Primer sequences are reported in Table 1. 
 
 
Gene Forward-primer (3’ to 5’) Reverse-primer (3’ to 5’) 
β-actin 
MMP-9 
MMP-2 
TIMP-1 
TIMP-2 
CTC TCC CTC ACG CCA TCC TG 
CGA CGG CAA GGA CGG C 
CGG TTT ATT TGG CGG ACA GTG AC 
TGG CAT CCT CTT GTT GCT ATC ACT G 
TGC AGA CGT AGT GAT CAG AGC CAA A 
TCA CGC ACG ATT TCC CTC TCA G 
GTA AGT GGG GAT CAC GAC GC 
ATT CCC TGC GAA GAA CAC AGC 
TGA ATT TAG CCC TTA TGA CCA GGT CC 
AAC TCG ATG TCT TTG TCA GGT CCT T 
 
Table 1.  Primers used for quantitative real-time PCR. 
 
Data analysis 
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Amplification, detection, and data analysis were performed using the ABI PRISM 7000 sequence 
detection system (Applied BioSystem, Foster City, CA). The quantification of mRNA levels was 
obtained by a method of relative quantification, the Delta-Delta Ct method (2-DDCt), following 
the instructions of the manufacturer (Applied Biosystems). The mice treated with saline or plus 
SB216763 have been used as internal calibrator of the samples. Once set the threshold line and 
the baseline, the corrispective Ct values were calculated. For each sample were calculated: 
 
1. DCtn= Ctn(gene) - Ctn (β-actin) 
2. DDCtn= Ctn(sample) - Ctn (internal calibrator) 
3. Relative Quantification= 2-DDCtn(sample) 
 
In this way for each sample has been calculated a value which represents the relative genic 
quantification, compared to the sample used as internal calibrator and considered of value 1. 
 
 
3.7  Cell culture and treatment 
 
A549 cells were cultured at in Dulbecco's modified Eagle's medium (EuroClone; Milano) 
supplemented with L-glutamine (2 mM), glucosio (4,5 g/L) e Na-pyruvate, penicilline (100 
U/ml), streptomycine (100 μg/ml) (Euroclone) and 10% fetal bovine serum (FCS, EuroClone) at 
37 °C,  in a humidified incubator with an atmosphere of 5% CO2.  
 
Gene silencing - RNA interference (RNAi)  
 
RNA interference (RNAi) is a process within living cells that moderates the activity of their 
genes. Two types of small ribonucleic acid (RNA) molecules – microRNA (miRNA) and small 
interfering RNA (siRNA) – are central to RNA interference. RNAs are the direct products of 
genes, and these small RNAs can bind to other specific messenger RNA (mRNA) molecules and 
either increase or decrease their activity, for example by preventing an mRNA from producing a 
protein. RNA interference has an important role in defending cells against parasitic genes – 
viruses and transposons – but also in directing development as well as gene expression in general.  
In this work we used RNAi to down-modulate GSK-3α and GSK-3β expression. In particular we 
chose siRNA oligos provided by Dharmacon, Thermo Scientific (Waltham, MA): (Table 2), a 
control oligo without target called SCRAMBLE (SCR), and a siGLO GREEN oligo, used to 
verify transfection efficiency.  
1.5X105 cells were seeded on 6 wells plates in DMEM medium without antibiotics. Once reached 
a minimum of 60% confluence, oligonucleotides (140 pmol/well) were diluted in OPTIMEME 
medium and combined with lipofectamine. Oligonucleotides-Lipofectamine complexes, were 
then added to each well. Transfection efficiency was monitored 48 hour later through flow 
cytometry, assessing the percentage of siGLO-GREEN positive cells. Cell were stimulated 48 
hours later, after 24 hours of serum starvation.  
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The down modulation of GSK-3α and GSK-3β genes was verified through western blot and real-
time PCR analysis. 
 
Gene Oligonucleotides sequences 
GSK-3α UCACAAGCUUUAACUGAGA 
GSK-3β GAUCAUUUGGUGUGGUAUA 
 
Table 2: siRNA oligonucleotides sequences 
 
Cell treatment 
 
After transfection and 24 hours of serum starvation, cells were stimulated with TNFa (15 ng/mL) 
and eventually pre-treated with specific inhibitors. Analysis were then performed 24 or 48 hours 
after stimulation. 
 
3.8  Statistical analysis 
 
All data are expressed as means ± S.E.M. Statistical differences among groups were determined 
using Student’s test or one-way ANOVA test.. Where needed in the case of failure of the 
normality tests, analyses were followed by Tukey’s test. Significance was defined at the p < 0.05 
level unless otherwise stated. 
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4. RESULTS 
 
4.1  In vivo Results (BLM mouse model) 
 
In vivo GSK-3 inhibition has a protective effect on BLM-induced lung inflammation and 
fibrosis 
 
C57BL/6N mice were randomized into 3 different subgroups: one treated with saline (PBS) a 
second one treated BLM plus vehicle and the last one treated with BLM plus SB216763. The 
SB216763-treated group received the inhibitor every 48 hours until sacrifice at day 7 or 28. At 
the time of sacrifice, mice underwent bronchoalveolar lavage (BAL) and a mean volume of 1.3 
mL of BAL fluid (BALF) was obtained. Lungs were then collected and each lobe was separately 
analyzed by the pathologist. As previously described [90], BLM induced a significant alveolitis at 
day 7 and lung fibrosis at day 28, while SB21 treatment confirmed his anti-inflammatory and 
anti-fibrotic potential, as shown in Figure 1 and 2. 
In particular, BLM-treated mice presented a significant increase in BALF cell count at day 7, 
(5,7x106 ± 2,1x106 cells/ml); in the BLM+SB216763 group BALF cell count was found 
significantly reduced (3,2x106 ± 1,4x106 cells/ml, p<0.05) (Figure 1). PBS treated mice did not 
present alveolitis at this time point. The same trend was confirmed at day 28 (data not shown). 
Histologic analysis of lungs collected at day 7 showed a similar behaviour of inflammatory 
infiltrate.  
 
Figure 1. SB216763 reduces BLM-induced alveolitis at day 7 (**) means p<0.05 
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The pathologic score for epithelial alveolar cell cuboidalization (a good index of epithelial 
damage) and for lung fibrosis resulted consistent with a significant effect of the GSK-3 inhibitor 
on the late fibrotic phase of the BLM-induced lung damage (Figure 2).  
 
 
Figure 2. SB216763 reduces BLM-induced epithelial alveolar cell cuboidalization (a) and lung fibrosis (b) at 
day 28 (*) p<0.01 
 
 
 
SB216763 reduces alveolar lymphocytosis and neutrophilia induced by BLM at day 7 
 
Differential BALF cell count showed that, in control mice, macrophages represented the 
main cell population; in contrast, mice exposed to BLM showed a strong increase of lymphocyte 
percentage as well as the appearance of the two sub-populations of neutrophils and eosinophils. 
The inhibition of GSK-3 with SB216763 significantly reduced the lymphocytes percentage (p < 
0.01) which was offset by the growth of macrophages (Table 1). This finding was in accordance 
with the previously published flow cytometric data, showing how the inhibition of GSK-3 
induced a reduction in CD3+ T Lymphocyte percentage at day + 7 after BLM administration [90]. 
The reduction of neutrophils and eosinophils percentage resulted not statistically significant. 
 
 
Experimental 
groups 
 total cells 
(x 106) 
macrophages 
(%) 
lymphocytes 
(%) 
neutrophils 
(%) 
eosinophils 
(%) 
Saline 
BLM 
BLM + SB216763 
n=5/experiment 
n=5/experiment 
n=5/experiment 
1.7 ± 0.8 
7.9 ± 4.3Ψ 
2.6 ± 1.8** 
96 ± 1.2 
62 ± 4.8 
87 ± 6.4* 
4 ± 3.2 
26 ± 7.0 
11 ± 6.1** 
0 
10 ± 6.3 
2 ± 1.5 
0 
2 ± 1.5 
0 
 
Table 1. Influence of GSK-3 inhibitor SB216763 on BALF cell number and composition at day 7. Data are 
given as mean ± S.D. of three independent animal trials. (Ψ) p <0.05 in comparison with saline group; (*) p<0.01 
and (**) p <0.05 in comparison with BLM group by Student’s t-test 
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SB216763 reduces BLM-driven MMP-9 and MMP-2 activity in BALFs 
 
We then performed a zymographic analysis of BALF supernatant, aimed at assessing the 
gelatinolytic activity of MMP-2 and MMP-9. Both MMP-9 and MMP-2 resulted elevated in the 
inflammatory phase (day 7) in mice treated with BLM compared to the PBS-instilled mice. 
Moreover, the in vivo treatment with SB216763 strongly reduced the levels of pro-MMP-9 (p 
<0.01) while it mildly but still significantly reduced both (pro- and active) forms of MMP-2 (p 
<0.05) as evinced by the densitometric analysis (Figure 3).  
 
 
 
Figure 3. MMP-9 and MMP-2 gelatinolytic activity measured in BALF supernatants by zymographic analysis 
at day 7 (a) Zymographic analysis for pro-MMP-9, pro- and active MMP-2. Data are confirmed by densitometric 
analysis of pro-MMP-9 (b), active MMP-2 (c) and pro-MMP-2 (d). (*) p <0,05; (**) p< 0.01 
 
 
In the late fibrotic phase (day 28) mice treated with BLM showed very high activity of MMP-2 in 
BALF; GSK-3 inhibition strongly reduced both pro- and active forms of MMP-2 (p< 0.01), as 
showed by the densitometric analysis (Figure 4). MMP-9 activity was almost undetectable at day 
28, both in BLM and in BLM + SB21673 group, with no difference compared to the PBS 
treatment (data not shown). 
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Figure 4. MMP-2 gelatinolytic activity measured in BALF supernatants by zymographic analysis at day 28.  
(a) Zymographic analysis. Densitometric analysis for active MMP-2 (b) and pro-MMP-2 (c). (**) p  <0.01 
 
 
SB216763 reduces MMP-9, MMP-2  and TIMP-1 secretion induced by BLM in BALFs. 
 
Once assessed the gelanotinolytic activity, we measured by Western Blot analysis the difference 
of secretion of MMPs and their inhibitors in BALFs between the cohorts of mice. In BLM-treated 
mice, MMP-9 and TIMP-1 protein levels were increased during inflammation (day 7), if 
compared to the controls (PBS). As shown in the blot image, the in vivo treatment with 
SB216763 strongly reduced pro-MMP-9 and its tissue inhibitor TIMP-1. On the contrary, as 
already suggested by zymographic analysis, MMP-2 was constitutively expressed in control mice 
and its levels were only slightly increased by BLM; SB216763 administration reduced MMP-2 to 
control levels, but the overall behaviour of this MMP was not relevant at day 7. (Figure 5a). 
Levels of TIMP-2 were not affected by BLM instillation (data not shown). BLM-treated mice 
sacrificed at day 28 showed very high protein expression of MMP-2 and only slightly increased 
levels of MMP-9 compared to the PBS, that was observed also by the zymographic analysis. 
Moreover, BLM-treated mice also had a greater secretion of TIMP-1 when compared with the 
controls. Finally, SB216763 down-modulated the protein levels of both MMP-2 and TIMP-1. 
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The same analysis has been performed on BALF of mice sacrificed at day 28. As expected 
from zimography, the effect of BLM was much more relevant for MMP-2 than for MMP-9 at this 
time point. Nonetheless, both MMPs increased after BLM instillation and SB216763 was shown 
to reduce their levels in the co-treated mice, restoring an almost physiological secretion. Finally, 
BLM treated mice presented a significant induction of TIMP-1, which was prevented by 
SB216763 regular administration during the 4 weeks before sacrifice (Figure 5b). 
 
 (a) 
(b) 
 
 
Figure 5. GSK-3 modulates protein expression of MMP-9, MMP-2 and TIMP-1. MMP-9, MMP-2 and TIMP-1 
protein levels were assessed in BALF supernatants by Western Blotting at day 7 (a) and day 28 (b). Images are 
representative of 3 mice/group of one of three independent experiments. According to molecular weight, it is 
possible to recognize pro-MMP-9 (105KDa), active MMP-9 (<105KDa), pro-MMP2 (75 KDa), active MMP-2 
(64KDa) and TIMP1 (27 KDa).  
 
 
 
SB216763 reduces MMP-9, TIMP-1, MMP-2 and TIMP-2 mRNA levels increased by BLM in 
BALF cells. 
 
After activity and secretion assessment, RNA was extracted from BALF cells and quantitative 
RT-PCR was performed in order to measure MMPs and TIMPs expression at a cellular level at 
day 7. BLM was shown to significantly increase MMP-2, MMP-9, TIMP-1 and TIMP-2 levels at 
this time point, while SB216763 administration was able to keep them comparable to those 
detected in control mice (Figure 6).  
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Figure 6. MMP-9 (A), TIMP-1 (B), MMP-2 (C) and TIMP-2 (D) transcript levels were quantified by Real 
Time PCR in inflammatory cells isolated from BALFs at day 7. Mice treated with BLM showed strong increase 
of MMP-9 and MMP2 gene expression levels compared to control mice. Also the mRNA levels of the tissue 
inhibitors, TIMP-1 and TIMP-2, were augmented by BLM treatment. Importantly, GSK-3 inhibition significantly 
reduced MMP-9, TIMP-1, MMP-2 and TIMP-2 transcript levels. (n = 6/10/10) (*) p <0.01; (**) p <0.05  
 
 
SB216763 downmodulates MMP-9, TIMP-1, MMP-2 and TIMP-2 overexpression induced by 
BLM in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells. 
 
To correlate BALF-derived data with tissue expression of MMPs and TIMPs, we performed 
histochemistry staining of formalin-fixed paraffin-embedded lung tissue. Only interstitial alveolar 
macrophages (iAM) and cuboidalized tipe II epithelial alveolar cells showed a detectable 
expression of metalloproteases and their inhibitors, at day 7.  
iAMs, the main population infiltrating lung interstitium at this time point, showed a strong 
staining for MMP9 (80±8.7%), TIMP1 (78±4.6%), and MMP2 (66±14%) and were moderately 
positive for TIMP-2 (55±28%) at day 7 after BLM instillation (Figure 7). In vivo SB216763 co-
treatment moderately reduced iAM staining for MMP9 (50±24%) and markedly down-modulated 
TIMP-1 (32±26%) and TIMP-2 (22±18%) positivity. MMP-2 expression, instead, was not 
significantly affected by GSK-3 inhibition.  
 
 46 
B
L
M
 +  
SB
216763 
B
L
M
 
MMP9 TIMP1 MMP2 TIMP2 
0 
20 
40 
60 
80 
100 
MMP9 TIMP1 MMP2 TIMP2 
Pa
th
ol
og
ic
 S
co
re
 (%
) 
** ** * 
BLM 
BLM + SB216763 
 
 
 
Figure 7. MMP and TIMP tissue expression was measured by the IC analysis of the lungs at day 7. BLM-
treated mice showed high positivity for MMP-9, TIMP-1, MMP-2 and TIMP-2 in alveolar macrophages (iAMs). 
GSK-3 inhibition down-modulated their expression. The pathologic scores in IC analysis represent the percentage of 
positive cells for each specific markers. Data are given as mean ± S.D. of three independent animal trials. (*) p < 
0.01 and (**) p< 0.05. 
 
Moreover, cuboidalized type II epithelial alveolar cells showed an 80% MMP-9 positivity in 
BLM-treated mice at day 7, strongly reduced to 40% in the BLM + SB216763 group (p >0.05, 
Figure 8). Cuboidalized type II epithelial alveolar cells also presented a relevant staining for 
MMP-2 (45%), TIMP-1 (55%) and TIMP-2; no epithelial staining for MMP-2 and TIMPs was 
detectable in SB216763-treated group (Figure 8). This finding is particularly significant, since 
cuboidalized type II pneumocytes represent a good marker of alveolar damage at day 7 and, at 
day 28, the degree of cuboidalization strongly correlate with the extent of fibrosis (Figure 2). 
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Figure 8. IHC staining of cuboidalized type II epithelial alveolar cells (a) MMP-9, TIMP-1, MMP-2 and TIMP-2 
were specifically expressed in injured alveolar cells that underwent cuboidalization (black arrows) and SB216763 
selectively reduced their expression. (b) The scheme summarizes the effects of GSK-3 inhibition in reducing the 
BLM-induced epithelial positivity for MMP-9, TIMP-1, MMP-2 and TIMP-2. In particular, BLM treated mice 
showed a moderate expression of MMP-9 in cuboidalized cells and SB216763 strongly decreased it, as showed in 
the mean ± S.D of 3 independent animal trials by the histogram. (**) p< 0.05 
 
Finally, preliminary data from IHC analysis at day 28 showed a virtually absent MMP-9 
expression in cuboidalized type II epithelial alveolar cells, while MMP-2 was significantly 
expressed, together with detectable TIMP-1 and -2. SB216763 treatment did not significantly 
affect MMP-9 expression, while reducing MMP-2. These results, even if preliminary, seem to 
confirm what detected in BALF. 
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4.2  In vitro results (A549 and MEF cells) 
 
GSK-3 silencing induce an increase of MMP-9 activity, downstream of TNFα , in A549 
epithelial alveolar cell line.  
 
Since damaged epithelial alveolar cells are currently believed to play the main role in IPF 
pathogenesis, we decided to further investigate, in vitro, the effect og GSK-3 inhibition on an 
epithelial alveolar type II cell line, A549. These cells are a NSCLC-derived celle line, but they 
are the most used type II epithelial alveolar cell model in IPF research. Thus, we reproduced 
GSK-3α and β inhibition through siRNA and used TNFα as a well known MMPs inducer in 
A549, via NF-κB pathway. siRNA allowed us to obtain a significant degree of GSK-3 inhibition, 
which was indeed higher than that obtained in vivo using SB216763. Mean transfection 
efficiency was 97% after 48 hours in 3 indipendents experiments, as shown in Figure 9; GSK-3 
silencing after 48 and 72 hours was significant for both paralogs, α and β, as shown by RT-PCR 
and Western Blot analysis (GSK-3 half life is 48 hours). Figure 9 shows flow cytometric analysis 
of transfection efficiency and RT-PCR and WB results for GSK-3 silencing.  
 
 
 
 
 
 
Figure 9. GSK-3 silencing in A549 cells. Mean transfection efficiency was 97% after 48 hours in 3 independent 
experiments. After 48 and 72 hours RT-PCR showed a degree of silencing of 80 and 85% for GSK-3α and of 40 and 
85% for β isoform, respectively. In terms of protein expression. GSK-3α presented a decrease of 85% and 90% 
while GSK-3β decreased by 90% and 95% at 48 and 72 hours after transfection, respectively. 
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After tranfection with SCRAMBLE or GSK-3 silencing and 24 hours of serum starvation, 
A549 cells were stimulated with TNFα 15 ng/mL for 24 or 48 hours. Medium was then collected 
and used for zymographic analysis. As shown in Figure 10 and as expected on the basis of data 
available in literature, MMP-9 activity was induced by TNFα stimulation. Moreover, GSK-3 
silencing significantly strengthen the TNFa effect on MMP-9 after 24 hours (p <0.01) and 48 
hours (p <0.05) (Figure 10). MMP2 resulted constitutively expressed by A549 untreated cells and 
no treatment affected its activity, as well as its protein and gene expression (data not shown).  
 
 
 
 
 
Figure 10. GSK-3 a and b silencing increases TNF-a induced MMP9 secretion in A549 cells. Zymographic 
analysis No difference was shown in MMP-2 activity. Densitometric results are represented as mean ± SD of 4 
independent experiments  with A549 cells (*) p <0.01; (**) p <0.05. 
 
 
GSK-3α  and β  silencing increase increases TNF-α  induced MMP-9 and TIMP-1 expression 
in A549 cells 
 
Western Blot analysis of cell culture medium at 24 and 48 hours after TNFa stimulation 
confirmed zymographic data in terms of MMP-9 protein secretion, with a significant 
strengthening of the stimulus in GSK-3 silenced cells (p <0.05). Moreover, TIMP-1 levels 
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resulted detectable in untreated A549 culture medium and the protein secretion was significantly 
increased in those cells underwent GSK-3 silencing (p <0.05). TNFα administration further 
increased TIMP-1 levels (p <0.05), with no significant difference following GSK-3 silencing 
(Figure 11)  
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Figure 11. GSK-3α and β silencing in A459 cells induced an increase in MMP9 protein expression 48 hours 
after stimulation with TNFα. MMP-9 and TIMP-1 levels have been measured at 24 hours (data not shown) and 48 
hours after TNFα stimulus. Densitometric analysis shows mean ±  SD of 4 independent experiments. (**) p <0,05 
compared to SCR-transfected unstimulated cells. 
 
Analysis of MMP-9 and TIMP-1 gene expression by RT-PCR analysis confirmed Western Blot 
results both at 24 hours (Figure 12) and 48 hours (data not shown). 
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Figure 12. GSK-3α and β silencing in A459 cells induced an increase in MMP9 protein expression 48 hours 
after stimulation with TNFα. MMP-9 and TIMP-1 mRNA levels have been measured at 24 hours and 48 hours 
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(data not shown) after TNFα stimulus. Histograms show mean ± SD of 3 independent experiments. (**) p <0,05 
compared to SCR-transfected unstimulated cells.  
 
 
GSK-3 silencing modulates phosphorilation of NF-kB p65 and MAPK p38, SAP/JNK and 
ERK downstream of TNF-a  
To deeply explore signalling pathways involved in TNFα-driven MMP-9 production we 
performed WB analysis to quantitate the phosphorilated (activated) isoforms of MAPK p38, 
SAP/JNK, ERK and p65. 48 hours after transfection with SCR or GSK-3 siRNA, A549 cells 
were stimulated with TNFα and collected at 0, 5, 15 and 40 minutes for WB analysis.  
 
As shown in Figure 13, TNFα induced p65 phosphorilation within the first 5 minutes; at 15 
minutes the degreee of phosphorilation was already declining, achieving a complete recovery of 
basal levels at 40 minutes. GSK-3 silencing increased phospho-p65 levels at 15 minutes after 
TNFα treatment. Total p65 was not affected by any treatment. 
 
Phosphorilated JNK2 but not JNK1 was already detectable at time 0 in control cells; TNFα 
increased phospho-JNK2 at 5 and 15 minutes, while inducing JNK1 phosphorilation. 
Phosphorylation degree of both JNK was back to basal level in 40 minutes. Surprisingly, GSK-3 
silencing was shown to reduce JNK2 phosphorilation at all time points, including basal levels, 
while strengthening JNK1 phosphorilation, mainly at 15 minutes. Total JNK1 and 2 were not 
affected by any treatment. 
 
Phosphorylated ERK1 and ERK2 were detectable at time 0 in untreated cells; TNFα 
induced an increase in phospho-ERK1 and 2, occurring within the first 5 minutes and stable until 
at least 40 minutes after stimulation.  GSK-3 silencing was able to sustain phosphorilation at all 
time points. Total not-phosphorilated ERK levels were not affected by gene silencing or TNFα 
stimulation at any time point. 
 
Finally, TNFα induced p38 phosphorilation within 5 minutes and until 15 minutes after 
stimulation, with a decrease towards basal levels at 40 minutes. GSK-3 silencing increased 
phosphor-p38 at all time points, sustaining phosphorilation until at least 40 minute. Once more, 
levels of unphosphorilated p38 were not affected by any treatment at any time point (Figure 13). 
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Figure 13. GSK-3 silencing modulates phosphorilation of NF-κB p65 and p38, JNK and ERK downstream of 
TNF-α . Tranfected A549 (SCR or GSK-3α and β siRNA) were stimulated with TNFα for 0, 5, 15 and 40 minutes. 
Proteins were extracted for WB analysis. MAPK and NF-κB pathways were investigated by phosphorilation 
assessment. “Total” forms of the investigated proteins were neither affected by GSK-3 silencing nor by TNFα 
stimulation.  
 
 
GSK-3 effect on MMP9 secretion seems to be regulated by interaction with ERK1,2, as 
demonstrated by using ERK1,2 phosphorilation inhibitor PD98059. 
 
Following phosphorilation data, specific inhibitors of p38 (SB203580) and ERK (PD98059) were 
used in order to investigate which of the above-mentioned pathways are directly involved in the 
modulation of MMP-9 secretion, downstream of.  Thus, A549 celle underwent or not GSK-3 
silencing were pre-treated with each specific inhibitor, simulated with TNFα and collected after 
48 hours. Supernatants were used for zymographic analysis. As shown in Figure 14, ERK1,2 
phosphorilation inhibitor PD98059 (10μM) induced a decrease of MMP-9 activity, if compared 
to TNFα stimulated cells not treated with the inhibitor. GSK-3 silencing did not counteract this 
PD98959-dependent effect. This suggested that GSK-3 could specifically interact with ERK1,2 
pathway when modulating MMP-9 activity.  
Results were confirmed by Western Blot analysis (data not shown). MMP-2 activity was 
constitutive and not affected by silencing, stimulation or ERK1,2 inhibition. 
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Figure 14. GSK-3 interact with ERK1,2 when modulating MMP-9 activity downstream of TNFα. 48 hours 
after transfection with  SCR or GSK-3α and β siRNA, A549 were pre-treated with PD98059 and underwent TNFα 
stimulation. Zymographic analysis was performed on supernatants 48 hours after stimulation.  
 
 
On the other hand, SB203580-mediated inhibition (10μM) of p38 phosphorilation did not affect 
MMP-9 activity dowstream of TNFα, both in SCR-transfected GSK-3-silenced cells (Figure 15). 
Results were confirmed by Western Blot analysis (data not shown). MMP-2 activity was 
constitutive and not affected by silencing, stimulation or inhibition of p38. 
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Figure 15. MAPK p38 pathway did not non modulate MMP-9 activity downstream of TNFα. 48 hours after 
transfection with  SCR or GSK-3α and β siRNA, A549 were pre-treated with SB203580 and underwent TNFα 
stimulation. Zymographic analysis was performed on supernatants 48 hours after stimulation.  
 
 
TIMP-1 expression is not modulated by MAPK p38 and ERK pathways 
 
Since previous data suggested a TIMP-1 induction consensual with MMP-9 under TNFα 
stimulation, we wanted to investigate the impact of p38 e ERK pathway inhibition by SB203580 
and PD98059, respectively, on TIMP-1 expression. 
Thus, 48 hours after transfection with SCR or GSK-3α and β siRNA, A549 were pre-treated 
with SB203580 or PD98059 and underwent TNFα stimulation. Western Blot analysis was 
performed on supernatants 48 hours after stimulation 
As shown in Figure 16, TIMP1 was consitutively expressed in untreated A549 and induced 
by TNFα; as previously demonstrated, GSK-3 silencing was able to strengthen TNFα-driven 
response. PD98059 pre-treatment, however, was unable to affect TIMP-1 expression, thus 
suggesting that TIMP-1 was not modulated by ERK1,2 phosphorilation in A549 cells (Figure 16). 
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Figure 16. TIMP1 expression was not modulated by ERK1,2 pathway.  48 hours after transfection with  SCR or 
GSK-3α and β siRNA, A549 were pre-treated with PD98059 and underwent TNFα stimulation. Western Blot 
analysis was performed on supernatants 48 hours after stimulation; TIMP-1 (27 KDa) expression was not influenced 
by treatment.   
 
Similarly, SB203580 pre-treatment did not influence TIMP-1 expression in any of the 
experimental conditions, thus suggesting that p38 MAPK pathway was not involved in TIMP-1 
modulation in A549 cells (Figure 17). 
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Figure 17. TIMP1 expression was not modulated by p38 pathway.  48 hours after transfection with  SCR or 
GSK-3α and β siRNA, A549 were pre-treated with SB203580 and underwent TNFα stimulation. Western Blot 
analysis was performed on supernatants 48 hours after stimulation; TIMP-1 (27 KDa) expression was not influenced 
by treatment.   
 
GSK-3 knock-out in murine embryonic fibroblasts (MEF) increased basal and TNFα-induced 
MMP-9 activity  
 
Finally, to preliminary explore the effect of GSK-3 inhibition in fibroblasts, whose 
importance is rising in the pathogenesis of IPF not only as a direct mediator of fibrosis, but also 
as a modulator of the process itself, we used a cell line of murine embryonic fibroblast available 
as wild type (WT) and knock out for GSK-3β (courtesy of Prof. Woodgett). In order to 
investigate the mechanism through which the kinase GSK-3 could modulate MMP-9 and MMP-2 
secretion and gene expression, we performed the zymographic analysis of the conditioned media 
collected from MEF WT and MEF KO in resting conditions or upon TNF-a stimulation at 12, 24 
or 48 hours; experiments were performed in serum starvation, as previously described. 
Interestingly, latent MMP-9 resulted to be constitutively secreted at all time points in KO cells 
only (Figure 18 a). MMP-2 was constitutively secreted both in WT and KO cells; GSK-3b KO 
increased 7 times and 4 times, at 24 and 48 hours respectively, the levels of the secreted zymogen 
in resting conditions compare to WT cells (p<0.01) (data not shown). 
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Zymographic analysis also showed that TNF-a induced MMP-9 secretion both in WT and in 
GSK-3b KO cells as early as 12 hours after stimulation. Moreover, the zymogen levels 
accumulated in media collected from MEF KO were higher than in MEF WT media at each time 
point (1.00 ± 0.00 versus 0.42 ± 0.16, p < 0.01 at 12 hours; 2.50 ± 0.26 versus 1.45 ± 0.30, p < 
0.05 at 24 hours; 5.70 ± 1.26 versus 2.00 ± 0.37, p < 0.01 at 48 hours) (Figure 18 b). 
On the other hand, pro-MMP-2 secretion seemed to be independent by TNF-a in WT cells 
but significantly increased in KO MEF. 
 
 
Figure 18. Zymographic analysis of MMP-2 and MMP-9 activity in supernatant of MEF WT and KO for 
GSK-3β under TNFα stimulation. (a) Zymographic gel representative for 3 independent trials. MEF WT and KO 
were plated and, once at confluence, cultered in FCS-free medium for 24 hours and then stimulated with TNF-α 15 
ng/ml. Medium was collected after 12, 24 or 48 hours and gelatinolytic activity was assessed. (b) and (c) 
Densitomeric analysis for  MMP-9 and MMP-2 secreted by MEF WT (black line) and KO (grey line). Results are 
displayed as mean ± SD of 3 independent experiments for MMP-9 (b) and MMP-2 (c) (*) p <0,05 if compared to 
MEF WT (**) p <0.01 if compared to MEF WT. 
 
These results were confirmed by Western Blot and RT-PCR analysis, and using primary mouse 
skin-derived fibroblasts undergone TNF-α stimulation and SB216763-mediated GSK-3 α and β 
inhibition (data not shown). 
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5. DISCUSSION AND CONCLUSIONS 
 
We previously demonstrated an anti-inflammatory and anti-fibrotic effect of GSK-3 
inhibition in a mouse model of BLM-induced pulmonary fibrosis [90]. As confirmed by 
BAARSMA et al. [88, 99], GSK-3 may thus be considered a potential therapeutic target in 
pulmonary fibrosis. In the present study we further investigated the GSK-3 role in signalling 
pathways specifically involved in the fibrogenesis, both in early and late phases of the process. In 
particular, we focused our attention on ECM remodelling, which is known to play a pivotal role 
in IPF. MMPs and TIMPs are indeed essential in the physiological turnover of the matrix and in 
the repair of disrupted basal membrane (BM). Moreover, apart from type II epithelial alveolar 
cells, fibroblasts and immune system, it is currently believed that also fibrotic ECM is not a 
simple consequence of the IPF pathogenesis, but can activate a pro-fibrotic positive feedback 
loop able to sustain or even drive the disease progression [100]. The impairment in the ECM 
turnover plays a role in many pulmonary disorders, including emphysema, asthma and lung 
carcinoma, and in local and metastatic cancer invasiveness. The importance of MMPs in the 
pathogenesis of IPF is still under careful investigation, since the aberrant deposition of ECM is a 
hallmark of the disease, but some evidence is already available for specific MMPs [37]. Studies 
from different groups have shown that there are MMPs highly expressed in IPF, playing diverse 
roles in the fibrotic response; however, the exact mechanisms are not well characterized [47].  
Increased levels of MMPs could sustain fibrosis progression by increasing ECM degradation and 
inducing mediators, as VEGF, which favour neo-angiogenesis and capillary permeabilitiy [101]. 
Moreover, in vivo use of the MMP inhibitor batimastat and knock-out mice for some MMPs 
(including MMP9 e MMP12) allowed to demonstrate that inhibition of MMPs can reduce the 
development of BLM-induced pulmonary fibrosis [39, 102, 103]. On the other hand, excessive 
levels of TIMPs could sustain an anti-collagenolytic microenvironment, thus promoting an 
aberrant collagen deposition; TIMP-1, for example, was found to be up-regulated in a BLM 
mouse model and TIMP3 resulted over-expressed in a cohort of IPF patients [101, 103]. MMP-2, 
MMP-9, TIMP-2 and TIMP-1 have been investigated in our study, exploring the possible role of 
the pleiotropic kinase GSK-3 in modulating their production and activity.  
Provided that the BLM-induced mouse model of lung fibrosis is not universally accepted as a 
trustable IPF model, mainly due to the role of inflammation in the development of fibrosis, it is 
still the most used in vivo model for studies about the pathogenesis of the disease and the first 
model where to test potential anti-fibrotic drugs before phase I clinical trials [93, 94]. Our data 
clearly showed, in this model, that MMPs and TIMPs are involved in the pathogenesis of BLM-
induced fibrosis. In particular, we demonstrated that MMP-2, MMP-9 and TIMP-1 levels were 
increased at day 7 in BALF of BLM treated mice. At this time point the process is still in the 
inflammatory phase and there is a consistent inflammatory infiltration of the lung. Alveolar 
macrophages, lymphocytes and neutrophils are recruited into the alveolar spaces and are believed 
to be responsible for the high levels of MMP-2, MMP-9 and TIMP-1 in the BALF. The main 
population infiltrating the lung parenchima was represented by iAMs which were shown by IHC 
analysis to strongly express MMP-2, MMP-9, TIMP-1 and -2. Noteworthy, we were able to show 
that not only the inflammatory cells were responsible for the release of these mediators, but also 
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type II epithelial alveolar cells. These cells already displayed at day 7 a significant degree of 
cuboidalization associated to a detectable expression of both MMPs and TIMPs, with a strong 
positivity for MMP-9 and TIMP-1. At day 28, when fibrosis was well established, we found in 
BALF an inversion in the hierarchy of MMPs; MMP-9 almost disappeared and MMP-2, which 
appeared less relevant in the early phases and consitutively expressed even in PBS-treated mice, 
became significantly increased in the BLM group, together with TIMP-1 and -2. Preliminary data 
from IHC analysis of lungs at day 28 confirmed this trend in type II epithelial alveolar cells.   
SB216763-mediated GSK-3 inhibition significantly reduced both BLM-induced 
inflammation and fibrosis in our mouse model, as already shown in our previous paper [90]. The 
present study also suggests a possible role of the kinase GSK-3 in modulating the balance 
between MMPs and TIMPs in the context of pulmonary fibrosis.  In vivo GSK-3 inhibition, 
indeed, strongly decreased MMP-9 activity and, to a lower extent, MMP-2 activity in BALF of 
BLM-treated mice. Moreover, SB216763 significantly reduced MMP-9, MMP-2, TIMP-1 and 
TIMP-2 production in iAMs and cuboidalized type II epithelial alveolar cells at day 7. At day 28 
GSK-3 inhibition resulted in a reduction of both MMP-9 and MMP-2 in the BALF, restoring an 
almost physiological secretion. At this time point the effect was much more prominent on MMP-
2, which has previously been shown to be more relevant in the fibrotic phase. Finally, the BLM-
induced increase of TIMP-1 was prevented by regular administration of SB216763 during the 4 
weeks before sacrifice. Even if preliminary, IHC results after GSK-3 inhbition were in line with 
BALF data, underlining once more the role of cuboidalized epithelial alveolar cells as main 
character of the play. Data from the BLM mouse model, in conclusion, showed that GSK-3 is 
involved, in vivo, in MMPs and TIMPs modulation following a pro-fibrotic lung injury. 
Nonetheless, it is not possible to assess if the effect of SB216763 is exerted directly on all the 
involved cell types or only indirectly through an anti-inflammatory effect. 
To address this question and further understand the molecular mechanisms underlying the 
role of GSK-3 in MMPs modulation, we then performed the above described in vitro experiments 
on single cell lines, namely A549 and MEF. As already shown, the in vitro effect of GSK-3 
silencing was the opposite of what expected on the basis of the in vivo results. We obtained, 
indeed, a significant MMP-9 induction downstream of TNFα stimulation and, in MEF knock out 
for GSK-3β, MMP-9 induction resulted detectable even without stimulation. Moreover, in A549 
cells, GSK-3 silencing increased TNFα-dependent MMP-9 production via the NF-κB pathway, 
as demonstrated by an increase in p65 phosphorilation levels.  The effect on MMP-9 also seemed 
to be dependent on the ERK1,2 pathway, since the ERK1,2 phosphorilation inhibitor PD98059 
was able to prevent MMP-9 production with or without GSK-3 silencing. On the contrary, p38 
was not involved in MMP-9 modulation, despite its phosphorilation resulting to be increased 
after GSK-3 silencing. Finally, the role of GSK-3 in MAPK SAP/JNK pathway needs to be 
further investigated, since GSK-3 silencing reduced JNK2 phosphorilation while increasing 
JNK1 phosphorilation, in our experiments. Concerning TIMP-1, which appeared to be 
constitutively expressed and increased after GSK-3 silencing in A549 cells, we can only say that 
this was not dependent on an interaction with ERK1,2 or p38 pathway.  
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At present, in vitro results are clearly in contrast with those obtained in the mouse model: the 
only common feature is represented by the finding that GSK-3 is involved in the modulation of 
MMPs and TIMPs in different cell types. The effect of this modulation, however, points at the 
kinase as at a positive modulator in vivo, while its inhibition in A549 and MEF cells results in a 
strong induction of MMP-9. Data concerning the prominent role of MMP-2 in the fibrotic phase 
of the BLM-induced process are not comparable with the present in vitro models, since they are 
all based on short-term cultures. Moreover, the TNFα-dependent MMP-9 strong induction in 
A549 cells after GSK-3 silencing suggests that GSK-3, as shown in other carcinoma-derived 
epithelial cell lines, could act as a regulator of Epithelial to Mesenchimal Transition (EMT) [24, 
104]. EMT, which physiologically happens, for example, during embryogenesis, is believed to be 
a crucial pathogenic step in tumor progression, but also in IPF; in this context, in particular, it is 
meant to be one of the main source of fibroblasts taking part into fibroblastic foci formation and 
aberrant ECM deposition, as previously described. In fact, GSK-3 has been shown to be a 
regulator of Snail in A549 cells, which is a transcriptional repressor of E-caderine, a well known 
epithelial marker whose down-regulation is indeed an EMT marker [89, 105]. Thus, MMP-9 
increase could be interpreted as an EMT marker itself, and this will be assessed in our future 
experiments.  
At this point of the discussion, there are two crucial questions rising from the analysis of our 
results. The first one is whether A549 or MEF and, generally, single cell lines can be considered 
a suitable model where to study IPF pathogenic mechanisms. As extensively discussed in the 
previous sections, IPF pathogenesis is more than complicated and involves a plethora of different 
pathways. As for many other diseases, its development is not based on a single aberration but 
mainly on a pro-fibrotic microenvironment, in which each pathway is relevant but is unlikely to 
be essential. Thus, it is not surprising that many promising anti-IPF molecules, acting on single 
pathways (e.g. TGF-β, Endothelin) did not achieve any results in vivo. As a confirmation of these 
theory, the only two drugs currently approved for IPF treatment, Pirfenidone and Nintedanib, 
exploit a multiple targets strategy to disrupt (only partially, unfortunately) the pathogenic 
mechanisms and slower the disease progression [18, 35]. Moreover, A549 are a carcinoma-
derived cell line and MEF an embryonic one, and this implicates a “cell mood” completely 
different from that found in IPF, with a different signalling background that is expected to 
differently react to stimulation (including TNFα or GSK-3 inhibition). A good example is 
represented by fibroblasts: MRC5 cells, a human lung embryonic cell line, display a significantly 
different behaviour and cell growth if compared with primary lung fibroblast; but the difference 
is even more significant when comparing normal fibroblasts with IPF fibroblasts, which present a 
markedly decreased cell growth rate and response to stimuli, including TGF-β. Finally, it has 
clearly been shown that there is not a single cell type on which IPF development is based; type II 
epithelial alveolar cells can be the main character of the play, maybe, but fibroblasts are also 
essential and definitely far from being mere executors. The importance of ECM is rising, as well, 
as a fundamental part of the microenvironment and also leucocytes, that have been put aside for 
years together with the role of inflammation in the pathogenesis of the disease, are now coming 
back in the main theories as modulators more than as effectors (e.g. M2 macrophages) [106]. 
Thus, single cell cultures are likely to be replaced by multiple cell culture systems and cell lines 
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must leave their place to primary cells; this is the direction of our future studies, and we are 
already taking part in the development of a new in vitro model, based on the association between 
long term 3D fibroblast culture, resembling fibroblastic foci and including a significant 
deposition of ECM, and epithelial alveolar cells. This will hopefully be the kind of model where 
definitely explore the role of GSK-3 in the modulation of ECM turnover. 
The second and final question is whether GSK-3 silencing or knock-out can be the best 
strategy to evaluate this potentially intriguing pharmacologic target. As extensively discussed in 
the introduction, GSK-3 is a pleiotropic kinase, implicate in many different pathways and with a 
fascinating huge number of control mechanisms that allow it to manage all of its tasks in an 
organized fashion. The long clinical experience with lithium teach us that in vivo inhibition of 
this kinase is not only safe, despite the multiple implications, but also that this safety is likely due 
to the partial inhibition that lithium exerts on GSK-3, that may be optimal for dampening GSK-
3's self-activating mechanisms in disease processes while allowing GSK-3 to fulfil, unhindered, 
its many other cellular actions [107]. On the basis of this idea, the pharmacologic in vivo 
inhibition performed in our mouse model is not only closer to the possible application in clinical 
practice, but also more suitable than in vitro experiments to really assess the role of the kinase 
and the actual potential of its inhibition. In addition to the potential benefit of only partial 
inhibition of GSK-3, in terms of future applications, the development of disease-selective 
inhibitors of GSK-3 will hopefully be possible, based on the awareness of the specific 
mechanisms that regulate GSK-3 and that depend on GSK-3 in the specific pathologic context.  
In conclusion, our study gives some hints but we are still far from completely understanding 
the role of GSK-3 in the pathogenesis of pulmonary fibrosis and available data present some 
controversies [87, 88]. Due to its implications at different levels in so many pathways involved in 
development of fibrosis, it remains a fascinating target in the field of IPF, where the aim of the 
research is not to close a bad way but to disrupt a dangerous net.   
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